(19) Europäisches Patentamt
European Patent Office
Offic européen des brevets

(11) Publication numb r: **0 156 433 B1**

(12) # EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **27.02.91**

(51) Int. Cl.[5]: **C07D 237/20**, C07D 237/22, C07D 237/24, C07D 401/04, C07D 401/12, C07D 401/14, C07D 403/04, C07D 403/12, C07D 417/12, C07D 409/14, A61K 31/50

(21) Application number: **85200384.7**

(22) Date of filing: **15.03.85**

The file contains technical information submitted after the application was filed and not included in this specification

(54) **Anti-virally active pyridazinamines.**

(30) Priority: **26.03.84 US 593444**
15.02.85 US 702772

(43) Date of publication of application:
02.10.85 Bulletin 85/40

(45) Publication of the grant of the patent:
27.02.91 Bulletin 91/09

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited:
EP-A- 0 055 583
US-A- 2 985 657
US-A- 4 104 385

J. Med. Chem. 6, 541-544 (1963)

J. Med. Chem. 8, 104-107 (1965)

(73) Proprietor: **JANSSEN PHARMACEUTICA N.V.**
Turnhoutsebaan 30
B-2340 Beerse(BE)

(72) Inventor: **Stokbroekx, Raymond Antoine**
Rode Kruisstraat 13
B-2340 Beerse(BE)
Inventor: **Van der Aa, Marcel Jozef Maria**
Kattenberg 139
B-2460 Kasterlee(BE)
Inventor: **Willems, Joannes Josephus Maria**
Tweesprongdreef 4
B-2360 Oud-Turnhout(BE)
Inventor: **Luyckx, Marcel Gerebernus Maria**
Eksterstraat 24
B-2440 Geel(BE)

EP 0 156 433 B1

J. Med. Chem. 15, 295-301 (1972)	
Farmacja Polska (1965) 21, 758-760	
Acta Chim. Acad. Hung. (1967) 52, 283-299	
Farmaco Ed. Sci. (1969) 24, 919-929	
J. Med. Chem. 18 , 741-746 (1975)	

Description

The present invention is concerned with anti-viral agents, pharmaceutical compositions containing these agents.

Viral infections are generally taught to be responsible for a number of diseases of various nature such as, for example, rabies, hepatitis, herpes, common cold, etc... More particularly, the latter disease is widely spread throughout the world and is a major cause of sickness and absence from work. An agent capable of treating said disease would be a great benefit to mankind and certainly be of great economic importance.

Up until now no such agents are available and there exists no established chemotherapeutic agent against the said disease.

The present invention discloses the useful anti-viral properties of a number of pyridazine derivatives and their use in the treatment of viral diseases. Some of the pyridazinamines of the present invention are known in the art as intermediates for the synthesis of other useful compounds or as compounds having certain pharmacological properties. These compounds and a number of structurally closely related compounds can be found in the following references.

In J. Med. Chem. 24 , 59-63 (1981) there are described a number of 1 H -imidazolyl-pyridazines, while in European Patent Number 55,583, U.S. Patent Numbers 4,110,450, 4,104,385 and 2,985,657 a number of piperazinyl, pyrrolidinyl and piperidinyl substituted pyridazines are described as intermediates. In European Patent Number 9,655 3-chloro-6-[-4-(2-methoxyphenyl)-1-piperazinyl]pyridazine and 1-chloro-4-(4-hydroxypiperidino)phtalazine are also described as intermediates. Moreover a number of substituted 1-piperazinyl-pyridazines are described in J. Med. Chem. 6, 541-4 (1963), in ibid. 8 , 104-107 (1965) and ibid. 15 , 295-301 (1972) as compounds having adrenolytic, antihistaminic or analgesic activity. In Farmacja Polska 21 , 758-760 (1965) mentioned in Chem. Abst. 65 3865q (1966) there are disclosed a number of phtalazine derivatives of which some have hypotensive activity. Acta Chim. Acad. Hung. 52 , 283-299 (1967) mentioned in Chem. Abst. 67 73577m (1967) discloses a group of substituted piperazine and pyridazine of which some are taught to possess anti-ulcer activity. Farmaco, Ed. Sci. 24 , 919-929 (1969) mentioned in Chem. Abst. 72 121471z (1970) describes a group of hydrazinopyridazines with hypotensive activity as well as a number of piperidinylpyridazines as intermediates. J. Med. Chem. 18 , 741-746 (1975) concerns 3-hydrazinopyridazine derivatives having antihypertensive properties as well as a number of piperazinyl-pyridazines for use as intermediates.

The compounds of the present invention differ from the cited prior-art compounds by the specific substitution on the pyridazine moiety and particularly by their useful anti-viral properties.

According to the present invention, there are provided anti-virally active pyridazinamines which may structurally be represented by the formula



(I),

the pharmaceutically acceptable acid-addition salts and/or possible stereochemically isomeric forms and/or possible tautomeric forms thereof, wherein

R^1 is a member selected from the group consisting of hydrogen, halo, 1 H -imidazol-1-yl, C_{1-6} alkyloxy, aryloxy, C_{1-6}alkylthio, arylthio, hydroxy, mercapto, amino, C_{1-6}alkylsulfinyl, C_{1-6}alkylsulfonyl, cyano, C_{1-6} alkyloxycarbonyl, C_{1-6}alkylcarbonyl, and C_{1-6}alkyl; wherein aryl in the definition of R^1 is phenyl optionally substituted with up to three substituents each independently selected from halo, nitro and C_{1-6}alkyl;

R^2 and R^3 are, each independently, members selected from the group consisting of hydrogen and C_{1-6}alkyl, or R^2 and R^3 combined may form a bivalent radical of formula -CH = CH-CH = CH-;

A is a bivalent radical of formula:



wherein one of the hydrogen atoms within the radical C_mH_{2m}-$C_{m-1}H_{2(m-1)}$ or C_nH_{2n} may be replaced by C_{1-6}alkyl or aryl; said aryl being phenyl optionally substituted with up to three substituents each independently selected from halo;

m and n are, each independently, integers of from 1 to 4 inclusive, the sum of m and n being 3, 4 or 5;

R^4 is a member selected from the group consisting of hydrogen; C_{1-6}alkyl; aryl; thiazolyl; pyrimidinyl; quinolinyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; Ar^1C_{1-6}alkyl; diphenyl C_{1-6}alkyl; phenyl being substituted with Ar^2carbonyl; pyridinyl, being optionally substituted with cyano or C_{1-6}alkyl; cyclohexyl and cyclohexenyl both being optionally substituted with up to two substituents independently selected from the group consisting of cyano and Ar^3;

wherein aryl in the definition of R^4 is phenyl, optionally substituted with up to 3 substituents, each independently selected from halo, C_{1-6}alkyl, trifluoromethyl, nitro, C_{1-6} alkyloxy, amino, hydroxy and C_{1-6}alkyloxycarbonyl;

Ar^1 is phenyl optionally substituted with up to 3 substituents each independently selected from C_{1-6}alkyl;

Ar^2 is phenyl optionally substituted with up to 3 substituents each independently selected from halo;

Ar^3 is phenyl optionally substituted with up to 3 substituents each independently selected from halo;

R^5 is hydrogen; C_{1-6}alkyl; aryl; hydroxy; C_{1-6}alkyloxy; Ar^4oxy; C_{1-6}alkyloxy being substituted with morpholine, pyrrolidine or piperidine; amino; (C_{1-6}alkyloxycarbonyl)amino; Ar^5amino; (Ar^6)(C_{1-6}alkyl)-amino; (phenyl C_{1-6}alkyl)amino; (Phenyl C_{2-6}alkenyl)amino; (phenyl C_{2-6}alkenyl)(C_{1-6} alkyl)amino; phenylcarbonyloxy;

Ar^4 is phenyl optionally substituted with up to 3 substituents each independently selected from halo and C_{1-6}alkyl;

Ar^5 is phenyl optionally substituted with up to 3 substituents each independently selected from halo, C_{1-6} alkyl, trifluoromethyl:

Ar^6 is phenyl optionally substituted with up to 3 substituents each independently selected from C_{1-6}alkyl;

R^6 is hydrogen; aryl; C_{1-6}alkyl; (C_{1-6} alkylcarbonyl amino) C_{1-6} alkyl, Ar^7C_{1-6}alkyl; Ar^8carbonyl C_{1-6}alkyl; aminocarbonyl; Ar^9carbonyl; phenylaminocarbonyl; (phenyl C_{1-6}-alkyl)carbonyl, C_{1-6}alkyloxycarbonyl; indolyl; pyridinyl;

Ar^7 is phenyl optionally substituted with up to 3 substituents each independently selected from halo and C_{1-6}alkyl;

Ar^8 is phenyl optionally substituted with up to 3 substituents each independently selected from halo;

Ar^9 is phenyl optionally substituted with up to 3 substituents each independently selected from halo and trifluoromethyl;

R^7 and R^8 are, each independently, members selected from the group consisting of hydrogen, C_{1-6}alkyl, aryl, $Ar^{10}C_{1-6}$-alkyl and pyridinyl;wherein Ar^{10} is phenyl optionally substituted with up to 3 substituents each independently selected from halo;

wherein aryl as in the definitions of R^5, R^6, R^7 and R^8 is phenyl, being optionally substituted with up to 3 substituents, each independently selected from the group consisting of halo, C_{1-6}alkyl, trifluoromethyl, nitro, amino, C_{1-6}alkyloxy, hydroxy and C_{1-6}alkyloxycarbonyl; thienyl; and naphthalenyl.

As used in the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo; " C_{1-6}alkyl" includes straight and branched saturated hydrocarbon radicals, having from 1 to 6 carbon atoms, such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dim thylethyl, propyl, butyl, p ntyl hexyl "C_{2-6} alkenyl" refers to alkenyl radicals having from 2 to 6 carbon atoms, such as, for example, 2-prop nyl, 2-

butenyl, 3-butenyl, 2-pentenyl

The compounds of formula (I) can generally be prepared by N-alkylating an amine of formula (II) with a reagent of formula (III) following art-known N-alkylating procedures.



In (III) W represents an appropriate reactive leaving group such as, for example, halo, i.e. fluoro, chloro, bromo or iodo, or a sulfonyloxy group, e.g. methylsulfonyloxy or 4-methylphenylsulfonyloxy, a C_{1-6}alkyloxy or C_{1-6}alkylthio group.

The alkylation reactions can conveniently be conducted in an inert organic solvent such as, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene a C_{1-6} alkanol, e.g., methanol, ethanol, 1-butanol; a ketone, e.g., 2-propanone, 4-methyl-2-pentanone; an ether, e.g., 1,4-dioxane, 1,1'-oxybisethane, tetranydrofuran; a dipolar aprotic solvent such as, for example, N , N -dimethylformamide (DMF); N , N -dimethylacetamide (DMA); dimethyl sulfoxide (DMSO); nitrobenzene; 1-methyl-2-pyrrolidinone. The addition of an appropriate base such as, for example, an alkali metal carbonate or hydrogen carbonate, sodium hydride or an organic base such as, for example, N , N -diethylethanamine or N -(-1-methylethyl)-2-propanamine may be utilized to pick up the acid which is liberated during the course of the reaction. In some circumstances the addition of an iodide salt. preferably an alkali metal iodide, is appropriate. The alkylation reactions can also be conducted by mixing and/or melting the reactants together, optionally in the presence of the bases mentioned hereinabove. Somewhat elevated temperatures may be used to enhance the rate of the reaction.

The compounds of formula (I) can also be converted into each other by an appropriate functional groupstransformation reaction. For example, the compounds of formula (I), wherein A is a radical of formula (b) wherein R^4 is a hydrogen radical, said compounds being represented by the formula (I-a), may be alkylated or acylated with a reagent of formula (IV) following the procedures described hereinabove for the preparation of (I) starting from (II) and (III), thus obtaining a compound of formula (I-b).



In (IV), W has the previously defined meaning, and R^{4-a} is as R^4, provided that it is not hydrogen.

The compounds of formula (I), wherein A is a radical of formula (b), wherein R^4 is C_{1-6}alkyl, Ar^1C_{1-6}alkyl, diphenyl C_{1-6}alkyl, cyclohexyl or cyclohexenyl, said R^4 being represented by R^{4-b} and said compounds by the formula (I-c), may be prepared by reductively N-alkylating a compound of formula (I-a) with an appropriate carbonyl-compound of formula $(R^{4-b-1})=C=O$, said $(R^{4-b-1})=C=O=$ being a compound of formula R^{4-b}-H, wherein a -CH_2-radical is oxidated to a carbonyl radical.



Said reductive N-alkylation reaction may conveniently be carried out by catalytically hydrogenating a stirred and heated mixture of the reactants in a suitable reaction-inert organic solvent according to art-known catalytic hydrogenating procedures. The reaction mixture may b stirred and/or heated in ord r to enhance

the reaction rate. Suitable solvents are, for example, water; C_{1-6} alkanols, e.g. methanol, ethanol, 2-propanol; cyclic ethers, e.g. 1,4-dioxane; halogenated hydrocarbons, e.g. trichloromethane; N , N -dimethylformamide; dimethyl sulfoxide; or a mixture of 2 or more of such solvents. The term "art-known catalytic hydrogenating procedures" means that the reaction is carried out under hydrogen atmosphere and in the presence of an appropriate catalyst such as, for example, palladium -on-charcoal, platinum-on-charcoal. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products it may be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene.

The compounds of formula (I), wherein A is a radical of formula (b), wherein R^4 is hydrogen can be converted into the corresponding compounds wherein R^4 is an optionally substituted 2-cyclohexenyl radical, by reacting the former compounds with an appropriate cyclohexanone derivative in the presence of a suitable solvent such as, for example, a hydrocarbon, e.g. benzene, methylbenzene In some cases it may be advantageous to supplement the reaction mixture with an appropriate acid, e.g. 4-methylsulfonic acid.

Or, conversely, the compounds of formula (I), wherein A is a radical of formula (b) wherein R^4 is C_{1-6} alkyloxycarbonyl or C_{1-6} alkylcarbonyl may be deacylated following art-known procedures, e.g. by reacting the starting compounds with an appropriate acidic or basic solution.

Similarly, the compounds of formula (I) wherein A is a radical of formula (c) wherein R^5 is (C_{1-6} alkyloxycarbonyl)amino may be converted into the corresponding amino-compounds.

The compounds of formula (I) wherein A is a radical of formula (c) wherein R^5 is hydroxy can be converted into the corresponding compounds of formula (I) wherein A is a radical of formula (d) by an elimination reaction. This can be accomplished by reacting the former compounds with a suitable acidic solution preferably at higher temperatures. Suitable acidic solutions contain one or more acids such as sulfuric, hydrochloric, acetic acids in admixture with water and/or an organic solvent, such as methanol, ethanol.

Or the starting hydroxy containing compounds can be reacted with an appropriate deshydratating agent such as, for example, phosphoryl chloride, thionyl chloride, phosphor trichloride, preferably in the presence of a suitable solvent such as, for example, pyridine, N , N -dimethylformamide (DMF).

The compounds of formula (I) containing a cyclohexenyl radical may be converted into the corresponding cyclohexyl containing compounds by an appropriate reduction procedure, e.g. by reacting the former compounds with a metal hydride, e.g. sodium borohydride, in a suitable solvent, e.g. an alkanol such as methanol, optionally in the presence of a base, e.g. sodium methoxide.

The compounds of formula (I), wherein R^1 is halo may be converted into the corresponding compounds wherein R^1 is C_{1-6} alkyloxy, aryloxy, C_{1-6} alkylthio or arylthio by reacting the said halo containing compounds with an appropriate aromatic or aliphatic alcohol or mercaptane. The said reaction may be conducted in an appropriate solvent such as, for example a ketone, e.g. 2-propanone, DMF, DMA. The addition of a suitable base such as, for example, an alkali metal hydride, e.g. sodium hydride, an alkali metal carbonate, e.g. sodium carbonate may be used to enhance the rate of the reaction. Alternatively, the starting halo compounds may be reacted with an appropriate alkali metal alkoxide or aryloxide in a suitable solvent, preferably in the corresponding alcohol, thus preparing the desired compounds of formula (I) wherein R^1 is C_{1-6} alkyloxy, aryloxy and aryl C_{1-6} alkyloxy.

The compounds of formula (I) wherein R^1 is arylmethyloxy may be converted into the corresponding hydroxy compounds following art-known procedures for the removal of the arylmethyl group, e.g. by reacting the starting compounds with an acidic solution or with hydrogen in the presence of an appropriate catalyst in a suitable solvent.

The compounds of formula (I), wherein R^1 is halo may be converted into the corresponding compounds wherein R^1 is hydrogen, following art-known hydrogenolysis procedures, i.e. by heating the starting compounds in a suitable solvent under hydrogen atmosphere in the presence of an appropriate catalyst, e.g. palladium-on-charcoal.

The compounds of formula (I), wherein R^1 is halo may further be converted into the corresponding mercapto containing compounds by reacting the former compounds with hydrogen sulfide or a reagent capable of generating hydrogen sulfide, e.g. thiourea in the presence of a base.

The compounds of formula (I) wherein R^1 is C_{1-6} alkyloxy carbonyl may be converted into the corresponding C_{1-6} alkylcarbonyl compounds by reacting the starting compounds with an appropriate ester in the presence of an alkali metal in a suitabl alcohol.

The compounds of formula (I) have basic properties and, consequently, they may be converted to their therapeutically active non-toxic acid-addition salt forms by treatment with appropriate acids, such as, for example, inorganic acids, such as hydrohalic acid, e.g. hydrochloric, hydrobromic, and sulfuric acid, nitric acid, phosphoric acid; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-

hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutan dioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethan sulfonic, benzenesulfonic, 4-methylbenz nesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic acid. Conversely the salt form can be converted by treatment with alkali into the free base form.

A number of intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies as described, for example, in U.S. Patent Numbers 2,997,472; 2,979,507; 2,997,474 and 3,002,976.

The intermediates of formula (II), wherein A is a radical of formula (b), wherein R^4 is other than hydrogen, said R^4 being represented by R^{4-a} and said intermediates by the formula (II-a), may be prepared by alkylating an amine of formula (V) with a reagent of formula (IV), thus yielding an intermediate of formula (VI), and subsequently eliminating the group P. In (V) and (VI) P is an appropriate protective group such as, for example, C_{1-6} alkyloxycarbonyl, arylmethoxycarbonyl, arylmethyl, arylsulfonyl. The elimination of P in (VI) may generally be carried out following art-known procedures such as, for example, by hydrolysis in alkaline or acidic medium.



The intermediates of formula (VI) may also be prepared by N-alkylating an amine of formula (VII) with a reagent of formula (VIII), following art-known N-alkylating procedures.



The reaction of (IV) with (V) and of (VII) with (VIII) may be conducted following the same procedures described hereinabove for the preparation of (I) starting from (II) and (III).

The intermediates of formula (II), wherein A is a radical of formula (c), wherein R^6 is hydrogen and R^5 is a radical of formula $-NR^9R^{10}$, said $-NR^9R^{10}$ being Ar^5amino, (Ar^6)(C_{1-6} alkyl)-amino, (phenylC_{1-6}alkyl)-amino, (phenyl C_{2-6} alkenyl)(C_{1-6} alkyl)amino, (phenyl C_{2-6} alkenyl)amino. said intermediates being represented by the formula (II-b), can conveniently be prepared by reductively N-alkylating a ketone of formula (IX) with an amine of formula (X), thus yielding an intermediate of formula (XI), and subsequently eliminating the protective group P. In (IX) and (XI), p has the previously described meaning.



(IX) (X) (XI) (II-b)

The said reductive amination may conveniently be carried out by catalytically hydrogenating a mixture of the reactants in a suitable reaction-inert medium, according to art-known procedures.

The intermediates of formula (II), wherein A is a bivalent radical of formula (c) wherein R^5 is hydroxy and R^6 is aryl, C_{1-6} alkyl or substituted C_{1-6}alkyl can be prepared by reacting (IX) with an appropriate Grignard reagent in a suitable solvent. The thus obtained hydroxy containing intermediates may be deprotected or further reacted with a suitable acidic solution in order to eliminate a water molecule and subsequently be deprotected thus preparing intermediates of formula (II) wherein A is a radical of formula (d).

The compounds of formula (I) show anti-viral activity and are particularly attractive due to their favourable therapeutic index, resulting from an acceptable low degree of cell toxicity, combined with a desirable anti-viral activity at low doses.

The useful anti-viral properties of the compounds of formula (I) are demonstrated in the following test procedure.

Rhinovirus Cythopatic Effect Test

Rhinovirus-sensitive Hela cells were seeded into Minimal Essential Medium (MEM) supplemented with 5% inactivated foetal calf serum and non essential amino acids. The seeded cells were incubated overnight at 37°C in a 5% CO_2 atmosphere. After 24 hours the cells were treated with solutions of the test compounds in a solvent containing 1 part by volume of DMSO and 7 parts by volume of MEM supplemented with 10% inactivated calf serum, or with the said solvent.

Both the solvent and drug treated cells were incubated for 3 hours at 37°C and subsequently a standardized inoculum of human rhinovirus was added. During a further incubation period at 33°C, the rhinovirus was allowed to grow in the Hela cells. Scoring of the results was delayed until a complete (100%) cytopathic effect was obtained in the virus controls (cells treated with solvent and virus).

Anti-viral activity was scored as the lowest concentration of the tested drug in µg/ml inhibiting at least 75% of the cytopathic effect observed in the virus controls.

Additionally, some of the compounds of the present invention show also analgetic and antitussive properties which properties can be demonstrated, for example by the Tail Withdrawal Reflex test and the Writhing Test described in Arzneim. Forsch., 25, 1505-1509 (1975) and in Arzneim. Forsch., 15 , 107-117 (1965).

In view of their useful pharmacological properties, the compounds of formula (I) and their acid-addition salts are very useful in the treatment of viral diseases.

In order to enhance the ease of administration, the subject compounds may be formulated into various pharmaceutical forms. To prepare the pharmaceutical compositions of this invention, an ffective amount of the particular compound, in base or acid-addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.

Thes pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percut aneously, or by parenteral injection. For example, in pr paring the compositions

in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents may be employed.

In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deletorious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.

Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and segregated multiples thereof.

In a further aspect of the present invention there is provided the use for the manufacture of an anti-viral medicament of a compound of formula (I), a pharmaceutically acceptable acid addition salt, a possible stereoisomeric or tautomeric form thereof. Suitable doses administered daily to subjects are varying from 0.01 mg to 1 g, preferably from 1 mg to 500 mg.

Preferred is the use for the manufacture of an anti-viral medicament of a compound having the formula



(I') ,

a pharmaceutically acceptable acid-addition salt and/or a possible stereoisomeric and/or a tautomeric form thereof, wherein R^1 , R^2 and R^3 have the previously defined meaning and A^1 is a bivalent radical having the formula (a), (b), (c) or (d); provided that

i) when R^1, R^2 and R^3 are hydrogen radicals and A^1 is a radical of formula (b), then R^4 is other than 3,3-diphenylpropyl;

ii) when R^1 is hydrogen and R^2 and R^3 combined form a bivalent CH = CH-CH = CH radical, then

is other than piperidinyl;

iii) when R^1 is halo, R^2 is C_{1-6} alkyl and R^3 is hydrogen, then

is other than piperidinyl and hexahydro-1 H -azepinyl;

iv) when R^1 is chloro, and A^1 is a bivalent radical of formula (b) then R^4 is other then (dimethoxyphenyl)-methyl, (dimethoxyphenyl)ethyl, (dimethoxyphenyl)methyl, α-methyl-phenethyl or (2-methylphenyl)-methyl.

Preferred compositions within the invention are those comprising an inert carrier and an anti-virally

effectiv amount of a compound of formula (I'), a pharmaceutically acceptable acid-addition salt and/or a possible stereochemically isomeric form and/or a tautomeric form thereof.

An additional feature of the present invention consists in the fact that some of the compounds of formula (I) and/ or th pharmaceutically acceptable acid-addition salts and/or possible stereoch mically isomeric and/or the possible tautomeric forms thereof are new, which compounds are represented by the formula



(I"),

wherein R^1, R^2 and R^3 have the previously described meaning and A^2 is a bivalent radical having the formula (a), (c), (d) or



(b-1),

wherein m and n have the previously described meaning and one of the hydrogen atoms within the radical C_mH_{2m}, $C_{m-1}H_{2(m-1)}$ or C_nH_{2n} may be replaced by C_{1-6} alkyl or aryl;
said aryl being phenyl optionally substituted with up to 3 substituents each independently selected from halo;

m and n are, each independently, integers of from 1 to 4 inclusive, the sum of m and n being 3, 4 or 5;

R^{4-c} is selected from aryl; thiazolyl; pyrimidinyl;quinolinyl; C_{1-6}alkylcarbonyl; C_{1-6}a lkyloxycarbonyl; Ar^1-C_{1-6}alkyl; diphenylC_{1-6}alkyl; phenyl being substituted with Ar^2carbonyl; pyridinyl, being optionally substituted with cyano or C_{1-6}alkyl; cyclohexyl and cyclohexenyl both being optionally substituted with up to two substituents independently selected from the group consisting of cyano and Ar^3 ; wherein aryl in the definition of R^{4-c} is as the aryl in the definition of R^4 in claim 1 and Ar^1, Ar^2 and Ar^3 are as defined hereinabove in the definitions of formula (I); provided that

i) when A^2 is a radical of formula (c) and R^5 is hydrogen, then R^5 is other than hydrogen, hydroxy or C_{1-6}alkyl;

ii) when R^2 and R^3 are hydrogen radicals and A is a radical of formula (b-1), then R^{4-c} is other than 3,3-diphenylpropyl;

iii) when R^2 and R^3 are hydrogen radicals and A^2 is a radical of formula (a), then R^1 is other than halo;

iv) when R^1 is chloro, R^2 and R^3 are hydrogen radicals and A^2 is a radical of formula (b-1), then R^{4-c} is other than 2-methoxyphenyl.

v) when R^1 is chloro, and A^2 is a bivalent radical of formula (b-1) then R^{4-c} is other then (dimethoxyphenyl)-methyl, (dimethoxyphenyl)ethyl, α -methylphenethyl or (2-methylphenyl)methyl.

vi) when R^1 is methoxy, and A^2 is a bivalent radical of formula (b-1), then R^{4-c} is other than (dimethoxyphenyl)ethyl or (dimethoxyphenyl)methyl.

Particularly preferred is the use for the manufacture of an anti-viral medicament of a compound having the formula (I") a pharmaceutically acceptable acid-addition salt and/or a possible stereochemically isomeric form and/or a possible tautomeric form thereof.

Particularly preferred compositions within the invention are those comprising an inert carrier and an anti-virally effective amount of a compound of formula (I"), a pharmaceutically acceptable acid-addition salt and/or a possible stereochemically isomeric form and/or a possible tautomeric form thereof.

Within the group of the said new compounds, those compounds of formula (I") are preferred wherein A^2 is a bivalent radical of formula (b-1), wherein R^{4-c} is aryl, pyridinyl, pyrimidinyl, C_{1-6}alkyloxycarbonyl, Ar^1C_{1-6} alkyl, diphenyl C_{1-6}alkyl, quinolinyl; or wherein A^2 is a bivalent radical of formula (c), wherein R^5 is hydrogen, aryl, Ar^5 amino, (Ar^6)-(C_{1-6} alkyl)amino, hydroxy, indolyl and R^6 is hydrogen, aryl, Ar^8carbonyl, (Ar^8carbonyl) C_{1-6}alkyl, or wherein A^2 is a bivalent radical of formula (d); wherein each aryl, Ar^1 Ar^5 Ar^6 Ar^8 and Ar^9 are as defined hereinabove.

Particularly preferred new compounds are those wherein the bivalent radical A^2 is as d fined for the preferred n w compounds and wherein R^2 and R^3 are both hydrog n radicals.

More particularly preferred new compounds are those wherein R^2, R^3 and A^2 are as defined for th

particularly preferred compounds and wherein in the said bivalent radical A^2 having the formula (b-1) m is the integer 2 or 3 and n is 2, in the radical A^2 having the formula (c) m is the integer 1 or 2 and n is the integer 2, and in the radical A^2 of formula (d), m is the integer 1 or 2 and n is the integer 2.

Especially pr ferred new compounds are those wherein R^2 , R^3 , A^2 , m and n are as defined for the previously mentioned more particularly preferred new compounds and wherein R^1 is halo, C_{1-6} alkyloxy, C_{1-6} alkylthio and cyano.

More especially preferred new compounds are those wherein R^2, R^3, A^2, m and n are as defined for the previously mentioned more particularly preferred new compounds, and wherein R^1 is halo.

The most preferred compounds within the invention are selected from the group consisting of 3-bromo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine, 3-chloro-6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-pyridazine and the pharmaceutically acceptable acid-addition salts thereof.

Some of the compounds of this invention may have several asymmetric centra in their structure. Pure stereoisomeric forms of the compounds of formula (I) may be obtained by art-known separation procedures. For example, diastereomers may be separated by selective crystallization or by application of chromatographic techniques, while enantiomers may be separated by the selective crystallization of their diastereomeric salts with optically active acids. Pure stereoisomeric forms may also be obtained by stereospecific syntheses starting from the corresponding stereoisomerically pure forms of the appropriate starting materials. Stereochemically isomeric forms of the compounds of formula (I) are intended to be embraced within the scope of this invention.

The following examples are intended to illustrate the scope of the present invention in all its aspects. Unless otherwise stated all parts therein are by weight.

EXAMPLES

A. Preparation of Intermediates.

Example 1

A mixture of 221 parts of 4-fluorobenzeneacetonitrile, 700 parts of sodium methoxide solution 30% and 900 parts of dimethylbenzene was stirred for 5 minutes. Then there were added dropwise 309 parts of methyl 2-propenoate (exothermic reaction: temperature rose to 65° C). Upon completion, stirring was continued overnight at reflux temperature. The methanol was distilled off till an internal temperature of 110° C was reached. After cooling, 1000 parts of a hydrochloric acid solution 6N were added dropwise and the whole was stirred and refluxed for 5 minutes. Upon cooling, the layers were separated. The organic phase was dried, filtered and evaporated. The residue was stirred and refluxed for 4 hours together with 500 parts of acetic acid, 500 parts of water and 500 parts of a hydrochloric acid solution. After cooling, the product was extracted with trichloromethane. The extract was washed successively with water, with a diluted sodium hydroxide solution and again with water till neutralization, dried, filtered and evaporated. The residue was crystallized from 2-propanol, yielding 134.5 parts of 1-(4-fluorophenyl)-4-oxocyclohexanecarbonitrile: mp. 91.8° C (intermediate 1).

Example 2

A mixture of 17.6 parts of 1-(phenylmethyl)piperazine, 8.4 parts of ethyl 4-fluorobenzoate and 45 parts of N , N -dimethylacetamide was stirred and refluxed for 22 hours. The reaction mixture was cooled and poured onto 500 parts of water. The product was extracted three times with benzene. The combined extracts were washed three times with a lot of water, dried, filtered and evaporated. The residue was stirred in hexane. The product was filtered off, washed with hexane and dried in vacuo, yielding 12.5 parts (77%) of ethyl 4-[4-(phenylmethyl)-1-piperazinyl]benzoate (intermediate 2).

Example 3

A mixture of 14 parts of ethyl 4-(methylamino)-1-piperidinecarboxylate, 13 parts of (3-chloro-1-pro-

penyl)benzene, 26.5 parts of sodium carbonate and 240 parts of 4-methyl-2-pentanone was stirred and refluxed ov r week-end using a water separator. The reaction mixture was cooled, water was added and the layers were separated. The organic phase was dried, filtered and evaporated. The residue was converted into the ethanedioate salt in 2-propanol and 2-propanone. The salt was filtered off and dried, yielding 23.4 parts of (E)-ethyl 4-[methyl(3-phenyl-2-propenyl)amino]-1-piperidinecarboxylate ethanedioate (1:1): mp. 160.2°C (intermediate 3).

Example 4

To a stirred mixture of 19 parts of 1-(phenylmethyl)-4-piperidinol, 15.2 parts of N , N -diethylethanamine and 180 parts of methylbenzene were added dropwise (slowly) 14 parts of benzoyl chloride. Upon completion, stirring was continued for 3 hours at room temperature. The formed hydrochloride salt of benzoyl chloride was filtered off and washed with methylbenzene. The filtrate was evaporated. The oily residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 18 parts (54%) of [1-(phenylmethyl)-4-piperidinyl] benzoate hydrochloride; mp. 225.9°C (intermediate 4).

Example 5

To a stirred mixture of 7.8 parts of sodium amide 5% in benzene and 135 parts of methylbenzene was added dropwise a solution of 11.7 parts of benzeneacetonitrile in 45 parts of methylbenzene at 25°C (cooling was necessary). After stirring for 30 minutes at 30°C, there was added dropwise a solution of 24.7 parts of ethyl 1-(phenylmethyl)-4-piperidinecarboxylate in 45 parts of methylbenzene at 30°C. Upon completion, stirring was continued overnight at 80°C. The reaction mixture was cooled, 12 parts of ethanol were added and the whole was poured into ice water. The layers were separated and the aqueous phase was neutralized with acetic acid. The oily product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 4-methyl-2-pentanone, yielding 12 parts (38%) of α-[hydroxy[1-(phenylmethyl)-4-piperidinyl]methylidene]-benzeneacetonitrile; mp. 191.9°C (intermediate 5).

To 200 parts of water were added carefully 200 parts of acetic acid while stirring and cooling. Then there were added dropwise (slowly) 368 parts of sulfuric acid. 90 Parts of α-[hydroxy[1-(phenylmethyl)-4-piperidinyl]methylidene]benzeneacetonitrile were added and the whole was stirred and refluxed overnight. The acetic acid was evaporated and the residue was poured into crushed ice. The mixture was alkalized with concentrate ammonium hydroxide and the oily product was extracted with trichloromethane. The extract was dried, filtered and evaporated, yielding 79 parts (96.3%) of 2-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]ethanone as a residue (intermediate 6).

Example 6

A mixture of 93 parts of N -(2-chloroethyl)-N -(3-chloropropyl)-4-methylbenzenesulfonamide, 30.3 parts of 2,3-dimethylbenzenamine, 63.6 parts of sodium carbonate, 1 part of potassium iodide and 240 parts of cyclohexanol was stirred and refluxed over weekend using a water separator. After cooling, the reaction mixture was poured into water. The product was extracted with methylbenzene. The extract was washed twice with water, dried, filtered and evaporated. The residue was crystallized from 2-propanol and a small amount of tetrahydrofuran. The product was filtered off and dried, yielding 47.8 parts (53.3%) of 1-(2,3-dimethylphenyl)hexahydro-4-[(4-methylphenyl)sulfonyl]-1 H -1,4-diazepine: mp. 86.2°C (intermediate 7).

In a similar manner there were also prepared:

1-[2-methoxy-5-(trifluoromethyl)phenyl]piperazine hydrochloride; mp. 226.8°C (intermediate 8);

1-[(4-methylphenyl)sulfonyl]-4-(2,4,6-trimethylphenyl)piperazine (intermediate 9);

1-(3,5-dichlorophenyl)hexahydro-4-[(4-methylphenyl)sulfonyl]-1 H -1,4-diazepine (intermediate 10);

1-(3-chlorophenyl)hexahydro-4-[(4-methylphenyl)sulfonyl]-1 H -1,4-diazepine: mp. 116.6°C (intermediate 11);

hexahydro-1-(2-methoxyphenyl)-4-[(4-methylphenyl)sulfonyl]-1 H -1,4-diazepine as a residue (intermediate 12); and

hexahydro-1-[(4-methylphenyl)sulfonyl]-4-[3-(trifluoromethyl)phenyl]-1 H -1,4-diazepine as a residue (intermediate 13).

Example 7

To a stirred mixture of 180 parts of 1-[(4-methylphenyl)sulfonyl]-4-(2,4,6-trimethylphenyl)piperazine and 450 parts of water were added dropwise 675 parts of sulfuric acid. The whole was stirred and refluxed for 4 hours. After cooling, the whole was treated with an ammonium hydroxide solution. The product was extracted with dichloromethane. The extract was dried, filtered and evaporated, yielding 70 parts (69%) of 1-(2,4,6-trimethylphenyl)piperazine as a residue (intermediate 14).

In a similar manner there were also prepared:

4-(3-methylphenyl)-4-piperidinecarboxamide (intermediate 15);

1-(2,3-dimethylphenyl)hexahydro-1 H -1,4-diazepine as a residue (intermediate 16);

hexahydro-1-(2-methoxyphenyl)-1 H -1,4-diazepine monohydrochloride; mp. 176.6° C (intermediate 17); and

hexahydro-1-[3-(trifluoromethyl)phenyl]-1 H -1,4-diazepine monohydrochloride; mp. 191.1° C (intermediate 18).

Example 8

A mixture of 7.9 parts of ethyl 3-oxo-1-pyrrolidinecarboxylate, 5.35 parts of 3-methylbenzenamine 1 part of a solution of thiophene in methanol 4% and 200 parts of methanol was hydrogenated at normal pressure and at 50° C with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 12.4 parts (100%) of ethyl 3-[(3-methylphenyl)amino]-1-pyrrolidinecarboxylate as a residue (intermediate 19).

In a similar manner there were also prepared:

N -(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinamine ethanedioate(1:1); mp. 151.6° C (intermediate 20);

N -phenyl-1-(phenylmethyl)-3-piperidinamine as a residue (intermediate 21);

ethyl 3-[(2,3-dimethylphenyl)amino]-1-pyrrolidinecarboxylate as a residue (intermediate 22);

ethyl 4-[[3-(trifluoromethyl)phenyl]amino]-1-piperidinecarboxylate monohydrochloride (intermediate 23);

N -(3-methylphenyl)-1-(phenylmethyl)-3-piperidinamine as a residue (intermediate 24); and

ethyl 3-[[3-(trifluoromethyl)phenyl]amino]-1-pyrrolidinecarboxylate as a residue (intermediate 25).

Example 9

To a stirred solution of 152 parts of 3-methyl-1-(phenylmethyl)-4-piperidinone in 900 parts of methylbenzene were added dropwise 218 parts of ethyl carbonochloridate at room temperature. Upon completion, stirring was continued overnight at reflux. After cooling, the reaction mixture was washed with water and hydrochloric acid, dried, filtered and evaporated. The residue was distilled, yielding 120.5 parts (83%) of ethyl 3-methyl-4-oxo-1-piperidinecarboxylate; bp. 98-105° C at 1 mm Hg pressure (intermediate 26).

Example 10

To a stirred and refluxed Grignard complex previously prepared starting from a mixture of 4.2 parts of 1-bromo-3-chlorobenzene, 5.4 parts of magnesium and 135 parts of tetrahydrofuran were added dropwise 19 parts of 1-(phenylmethyl)-3-piperidinone. Upon completion, stirring was continued for 1 hour at reflux temperature. After cooling, the reaction mixture was poured into ice water and 12.5 parts of acetic acid. The layers were separated. The aqueous phase was extract d with trichloromethane. The organic layer was washed with water, dried, filter d and vaporated. The residue was conv rted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 26 parts (76%) of 3-(3-chlorophenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride (intermediate 27).

In a similar manner there were also prepared:

ethyl 4-hydroxy-4-(2-thienyl)-1-piperidinecarboxylate; mp. 146.2° C; (intermediate 28):

ethyl 4-hydroxy-4-(1-naphthalenyl)-1-piperidinecarboxylate; mp. 109.2-114.8° C; (intermediate 29);
ethyl 3-(4-chloro-3-(trifluoromethyl)phenyl]-3-hydroxy-1-pyrrolidinecarboxylate as a residue; (intermedate 30);
ethyl 4-hydroxy-4-(2-naphthalenyl)-1-piperidinecarboxylate as a residue; (intermediate 31);
3-(3-methylphenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride (intermediate 32);
cis -3-methyl-4-(3-methylphenyl)-1-(phenylmethyl)-4-piperidinol as a residue (intermediate 33);
ethyl cis -4-(3-fluorophenyl)-4-hydroxy-3-methyl-1-piperidinecarboxylate as a residue (intermediate 34);
ethyl cis -4-hydroxy-3-methyl-4-(2-thienyl)-1-piperidinecarboxylate as a residue (intermediate 35);
ethyl 3-hydroxy-3-(2-thienyl)-1-piperidinecarboxylate (intermediate 36);
3-(3-fluorophenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride (intermediate 37);
ethyl 4-(2,3-dimethylphenyl)-4-hydroxy-1-piperidinecarboxylate (intermediate 38);
3-(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride (intermediate 39);
3-(3-methylphenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride (intermediate 40);
ethyl 3-[4-chloro-3-(trifluoromethyl)phenyl]-3-hydroxy-1-piperidinecarboxylate as a residue (intermediate 41);
3-(3-fluorophenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride (intermediate 42);
ethyl 4-hydroxy-4-(3-methoxyphenyl)-3-methyl-1-piperidinecarboxylate as a residue (intermediate 43); and
3-(3-methoxyphenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride (intermediate 44).

Example 11

A mixture of 7 parts of 3-(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride and 200 parts of a hydrochloric acid solution 6N was stirred and refluxed overnight. The reaction mixture was evaporated. Water was added and the base was liberated with ammonium hydroxide. The product was extracted with trichloromethane. The extract was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The first fraction was collected and the eluent was evaporated, yielding 0.7 parts (12%) of 5-(2,3-dimethylphenyl)-1,2,3,4-tetrahydro-1-(phenylmethyl)pyridine as a residue (intermediate 45). The second fraction was collected and the eluent was evaporated, yielding 5.3 parts (91%) of 5-(2,3-dimethylphenyl)-1,2,3-6-tetrahydro-1-(phenylmethyl)pyridine as a residue (intermediate 46).

Example 12

A mixture of 8 parts of 3-(3-methylphenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride and 150 parts of a hydrochloric acid solution 6N was stirred and refluxed for 3 hours. After cooling, the reaction mixture was evaporated, yielding 7.4 parts (100%) of 2,3-dihydro-4-(3-methylphenyl)-1-(phenylmethyl)-1 H -pyrrole hydrochloride as a residue (intermediate 47).

In a similar manner there were also prepared:

1,2,3,6-tetrahydro-5-(3-methylphenyl)-1-(phenylmethyl)pyridine as a residue (intermediate 48); and
5-(3-fluorophenyl)-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine hydrochloride (intermediate 49).

Example 13

To a stirred solution of 13 parts of 3-(3-chlorophenyl)-1-(phenylmethyl)-3-piperidinol in 270 parts of methylbenzene were added dropwise 10.9 parts of ethyl carbonochloridate at room temperature. Upon completion, stirring was continued overnight at reflux temperature. After cooling to room temperature, the whole was washed with water and hydrochloric acid. The organic layer was dried, filtered and evaporated, yielding 7 parts (58%) of ethyl 3-(3-chlorophenyl)-3-hydroxy-1-piperidinecarboxylate as a residue (intermediate 50).

Example 14

A mixture of 11.8 parts of N -(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinamine and 120 parts of

methanol was hydrogenated at normal pressure and at room temprature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (from 99:1 to 95:5 by volume) as eluent. Th pure fractions were collected and the eluent was evaporated. The residue was converted into the ethanedioate salt in 2-propanol and 2-propanone. The salt was filtered off and dried, yielding 7 parts (79.5%) of N (2,3-dimethylphenyl)-3-piperidinamine ethanedioate (1:1); mp. 161.6 °C (intermediate 51).

In a similar manner there were also prepared:

ethyl 4-(1-piperazinyl)benzoate; mp. 102.6 °C (intermediate 52);

(4-piperidinyl) benzoate hydrochloride; mp. 236.8 °C (intermediate 53);

N -phenyl-3-piperidinamine; mp. 79,8 °C (intermediate 54);

N -(3-methylphenyl)-3-piperidinamine as a residue (intermediate 55);

4-[(3-methylphenyl)amino]-4-piperidinecarboxamide as a residue (intermediate 56);

2-phenyl-1-(4-piperidinyl)ethanone hydrochloride; mp. 198.6 °C; (intermediate 57);

3-(3-methylphenyl)piperidine as a residue (intermediate 58);

3-(3-methylphenyl)-3-piperidinol hydrochloride (intermediate 59);

cis -3-methyl-4-(3-methylphenyl)-4-piperidinol as a residue (intermediate 60);

3-(3-fluorophenyl)-3-piperidinol hydrochloride (intermediate 61);

3-(2,3-dimethylphenyl)3-piperidinol hydrochloride hemihydrate; mp. 135.5 °C (intermediate 62);

3-(2,3-dimethylphenyl)piperidine as a residue (intermediate 63);

3-(3-methylphenyl)-3-pyrrolidinol (intermediate 64);

3-(3-methoxyphenyl)-3-piperidinol hydrochioride as a residue (intermediate 65);

3-(3-fluorophenyl)-3-pyrrolidinol hydrochloride as a residue (intermediate 66); and

3-(3-methoxyphenyl)-3-pyrrolidinol hydrochloride as a residue (intermediate 67).

Example 15

A mixture of 13.10 parts of ethyl 3-[(2,3-dimethylphenyl)amino]-1-pyrrolidinecarboxylate, 28 parts of potassium hydroxide and 240 parts of 2-propanol was stirred and refluxed for 6 hours. The reaction mixture was evaporated. The residue was taken up in water. The product was extracted with dichloromethane. The extract was dried, filtered and evaporated, yielding 6 parts (63%) of N -(2,3-dimethylphenyl)-3-pyrrolidinamine as a residue (intermediate 68).

In a similar manner there were also prepared:

(E)-N -methyl-N -(3-phenyl-2-propenyl)-4-piperidinamine dihydrochloride hemihydrate; mp. 240.2 °C (intermediate 69);

N -[3-(trifluoromethyl)phenyl]-4-piperidinamine dihydrobromide; mp. 253.2 °C (intermediate 70):

N-(3-methylphenyl)-3-pyrrolidinamine ethanedioate(1:2); mp. 180 °C (intermediate 71);

4-(2-thienyl)-4-piperidinol; mp. 145.9 °C (intermediate 72);

4-(1-naphthalenyl)-4-piperidinol; mp. 185.1-187.8 °C (intermediate 73);

3-[4-chloro-3-(trifluoromethyl)phenyl]-3-pyrrolidinol; mp. 138.4-142.1 °C (intermediate 74);

4-(2-naphthalenyl)-4-piperidinol (intermediate 75);

N -[3-(trifluoromethyl)phenyl]-3-pyrrolidinamine dihydrochloride (intermediate 76):

cis -4-(3-fluorophenyl)-3-methyl-4-piperidinol as a residue (intermediate 77);

cis -3-methyl-4-(2-thienyl)-4-piperidinol as a residue (intermediate 78);

3-(2-thienyl)-3-piperidinol (intermediate 79);

3-(3-chlorophenyl)-3-piperidinol hydrochloride (intermediate 80);

4-(2,3-dimethylphenyl)-4-piperidinol (intermediate 81);

4-(3-chlorophenyl)-3-methyl-4-piperidinol as a residue (intermediate 82);

3-[4-chloro-3-(trifluoromethyl)phenyl]-3-piperidinol (intermediate 83); and

4-(3-methoxyphenyl)-3-methyl-4-piperidinol as a residue (intermediate 84).

Exampl 16

A mixture of 3 parts of 3-(3-fluorophenyl)-3-piperidinol hydrochloride and 100 parts of a hydrochloric acid solution 6N was stirred and refluxed for 3 hours. The reaction mixture was evaporated. The residue was taken up in water and ammonium hydroxide. The product was extracted with trichloromethane. The

extract was washed with water, dried, filtered and evaporated, yielding 2.2 parts (96%) of 5-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine as a residue (intermediate 85).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

4-[4-chloro-3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine hydrochloride (intermediate 86);
1,2,3,6-tetrahydro-4-(2-thienyl)pyridine hydrochloride (intermediate 87);
1,2,3,6-tetrahydro-4-[3-(trifluoromethyl)phenyl]pyridine as a residue (intermediate 88);
1,2,3,6-tetrahydro-4-(1-naphthalenyl)pyridine hydrochloride; mp. 277.5 °C (intermediate 89);
1,2,3,6-tetrahydro-5-(3-methylphenyl)pyridine hydrochloride (intermediate 90);
3,4-dihydro-3-(2-thienyl)-1 H -pyrrole as a residue (intermediate 91); and
3-(2-thienyl)pyrrolidine as a residue (intermediate 92).

Example 17

A mixture of 6.5 parts of 5-(3-fluorophenyl)-1,2-3-6-tetrahydro-1-(phenylmethyl)pyridine hydrochloride and 120 parts of methanol was hydrogenated at normal pressure and at 50 °C with 1 part of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 4.5 parts (100%) of 3-(3-fluorophenyl)-piperidine hydrochloride as a residue (intermediate 93).

In a similar manner there were also prepared:
4-(2-thienyl)piperidine hydrochloride (intermediate 94); and
3-(3-methylphenyl)pyrrolidine hydrochloride as a residue (intermediate 95).

Example 18

A mixture of 21 parts of N -(3-methylphenyl)-1-(phenylmethyl)-4-piperidinamine dihydrochloride, 9 parts of poly(oxymethylene), 15 parts of potassium acetate, 2 parts of a solution of thiophene in methanol 4% and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 4 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated. From the residue, the free base was liberated with ammonium hydroxide and extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 2.4 parts (75%) of N -methyl-N -(3-methylphenyl)-1-(phenylmethyl)-4-piperidinamine dihydrochloride hemihydrate; mp. 201.3 °C (intermediate 96).

A mixture of 9 parts of N -methyl-N -(3-methylphenyl)-1-(phenylmethyl)-4-piperidinamine dihydrochloride hemihydrate and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated. The residue was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 1.5 parts (60.9%) of N -methyl-N -(3-methylphenyl)-4-piperidinamine dihydrochloride monohydrate; mp. 209.1 °C (intermediate 97).

B. Preparation of Final compounds

Example 19

A mixture of 47.6 parts of 1 H -imidazole, 33.6 parts of sodium hydride dispersion 50% and 750 parts of N , N -dim thylformamide was stirred at room temperature for 15 minutes. The resulting solution was added to 106 parts of 3,6-dichloropyridazine in 750 parts of N , N -dimethylformamide and the whole was further stirred for 2 days at room temperature. The product was extracted with trichloromethane. The extract was dried, filter d and evaporated. The residue was crystallized from methanol. The product was filter d off, washed with petroleumether and dried, yielding 48.5 parts of 3-chloro-6-(1 H -imidazol-1-yl)pyridazine; mp.

182.9° C (compound 1).

Example 20

A mixture of 3 parts of 3,5-dimethylphenol, 1.25 parts of sodium hydride dispersion 50% and 25 parts of N -N -dimethylformamide was stirred for 15 minutes. Then there was added a solution of 4.5 parts of 3-chloro-6-(1 H -imidazol-1-yl)pyridazine in 25 parts of N , N -dimethylformamide and the whole was stirred over weekend at 50° C. The reaction mixture was poured onto water and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 2-propanone, yielding 3.5 parts of 3-(3,5-dimethylphenoxy)-6-(1 H -imidazol-1-yl)pyridazine; mp. 169.8° C (compound 2).

In a similar manner there were also prepared:

3-(1 H -imidazol-1-yl)-6-(4-methylphenoxy)pyridazine; mp. 146.8° C (compound 3);

3-(1 H -imidazol-1-yl)-6-(3-nitrophenoxy)pyridazine; mp. 171.5° C (compound 4); and

3-(4-chlorophenoxy)-6-(1 H -imidazol-1-yl)-pyridazine; mp. 165.8° C (compound 5).

Example 21

A mixture of 4.5 parts of 3-chloro-6-(1 H -imidazol-1-yl)pyridazine, 3.2 parts of 4-bromophenol, 4.2 parts of sodium carbonate and 80 parts of 2-propanone was stirred and refluxed over weekend. The reaction mixture was evaporated and the residue was taken up in water and 2,2'-oxybispropane. The layers were separated. The organic phase was dried, filtered and evapoated. The residue was crystallized from 2-propanol, yielding 3.5 parts of 3-(4-bromophenoxy)-6-(1 H -imidazol-1-yl)pyridazine; mp. 168.4° C (compound 6).

Example 22

A mixture of 4.35 parts of 1-(4-fluorophenyl)-4-oxocyclohexanecarbonitrile, 3.3 parts of 1-(3-piperazinyl)-pyridazine, 0.2 parts of 4-methylbenzenesulfonic acid and 360 parts of methylbenzene was stirred and refluxed overnight using a water separator. The reaction mixture was cooled and evaporated, yielding 7.3 parts (100%) of 1-(4-fluoro phenyl)-4-[4-3-pyridazinyl)-1-piperazinyl]-3-cyclohexenecarbonitrile as a residue (compound 7).

To a stirred mixture of 7.3 parts of 1-(4-fluorophenyl)-4-[4-(3-pyridazinyl)-1-piperazinyl]-3-cyclohexenecarbonitrile, 1 part of sodium methoxide solution 30% and 240 parts of methanol were added portionwise 0.8 parts of sodium borohydride. Upon completion, stirring was continued overnight at room temperature. The reaction mixture was poured onto ice water and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 2-propanol, yielding 4.5 parts (61.5%) of 1-(4-fluorophenyl)-4-[4-(3-pyridazinyl)-1-piperazinyl]-cyclohexanecarbonitrile; mp. 188.7° C (compound 8).

Example 23

A mixture of 3.1 parts of 3,6-dichloropyridazine, 3 parts of 1-(2-fluorophenyl)piperazine, 3.2 parts of sodium carbonate, 0.1 parts of potassium iodide and 72 parts of N , N -dimethylformamide was stirred and heated over weekend at 60° c. The reaction mixture was poured into water. The precipitated product was filtered off and dissolved in trichloromethane. The organic layer was dried, filtered and evaporated. The residue was purified by filtration over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane, yielding 4.5 parts (77%) of 3-chloro-6-[4-(2-fluorophenyl)-1-piperazinyl]pyridazine; mp. 148.0° C (compound 9).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also pr pared:



base

No.	R^1	R^2	A	mp. in °C
10	Cl	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(2-C_2H_5-C_6H_4)	107.9
11		H	$(CH_2)_2$-N(-$(CH_2)_2$)-(3-CH_3-C_6H_4)	177.7
12	Cl	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(3-C_2H_5-C_6H_4)	119.8
13	Cl	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(5-CH_3-2-pyridinyl)	226.2
14	Cl	CH_3	$(CH_2)_2$-N(-$(CH_2)_2$)-(3-CH_3-C_6H_4)	152.7
15	Cl	H	$(CH_2)_2$-N(-$(CH_2)_2$)-[2,4,6-$(CH_3)_3$-C_6H_2]	149.8
16	Cl	CH_3	$(CH_2)_2$-N(-$(CH_2)_2$)-(3-Cl-C_6H_4)	163.5
17	Cl	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(2-Br-C_6H_4)	191.4
18	Cl	H	$(CH_2)_2$-CH(-$(CH_2)_2$)-NH-(3-CH_3-C_6H_4)	156.8
19	Cl	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(2,3-Cl_2-C_6H_3)	160.6
20	Cl	CH_3	$(CH_2)_2$-N(-$(CH_2)_2$)-(3-CF_3-C_6H_4)	176.6
21	Cl	H	$(CH_2)_2$-CH(-$(CH_2)_2$)-C_6H_5	122.7

22	Cl	H	$(CH_2)_2-CH(-(CH_2)_2)-(3-CH_3-C_6H_4)$	107.5
23	Cl	H	$(CH_2)_2-CH(-(CH_2)_2)-(3-CF_3-C_6H_4)$	69.8

Example 24

A mixture of 2.7 parts of 3,6-difluoropyridazine, 4.6 parts of 1-[3-(trifluoromethyl)phenyl]piperazine, 3.2 parts of sodium carbonate and 90 parts of N , N -dimethylformamide was stirred overnight at 60 °C. The reaction mixture was poured into water. The product was filtered off, washed with water and crystallized from 2-propanol, yielding 3 parts (46%) of 3-fluoro-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]pyridazine; mp. 131.5 °C (compound 24).

In a similar manner there were also prepared:

3-[4(2,3-dimethylphenyl)-1-piperazinyl]-6-fluoropyridazine; mp. 144.1 °C (compound 25);

3-fluoro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 128.1 °C (compound 26) and

3-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-fluoropyridazine; mp. 105.2 °C (compound 27).

Example 25

A mixture of 4.5 parts of 3,6-dichloropyridazine, 5.2 parts of 1,2,3,6-tetrahydro-4-(3-methylphenyl)-pyridine, 5.3 parts of sodium carbonate and 72 parts of N , N -dimethylformamide was stirred and heated overnight at about 70 °C. The reaction mixture was evaporated and water was added to the residue. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by filtration over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 2.1 parts (24%) of 3-chloro-6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]pyridazine; mp. 122.2 °C (compound 28).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:



	R^1	A	Salt or base	mp. in °C
29	Cl	$(CH_2)_2-N(-(CH_2)_2)-(4-CH_3O-C_6H_4)$	base	183.3
30	Cl	$CH_2-CH(CH_3)-N(-(CH_2)_2)-(4-CH_3O-C_6H_4)$	base	133.5
31	Cl	$(CH_2)_2-N(-(CH_2)_2)-(2\text{-thiazolyl})$	base	221.9
32	Cl	$(CH_2)_2-N(-(CH_2)_2)-(3-Cl-C_6H_4)$	base	146.6
33	Cl	$(CH_2)_2-N(-(CH_2)_2)-C_6H_5$	base	172.0
34	Cl	$(CH_2)_2-N(-(CH_2)_2)-(2-CH_3O-C_6H_4)$	base	144.5
35	Cl	$(CH_2)_2-N(-(CH_2)_2)-(4-CH_3-C_6H_4)$	base	188.6
36	Cl	$(CH_2)_2-N(-(CH_2)_2)-[3,4-(CH_3)_2-C_6H_3]$	base	162.6
37	Cl	$(CH_2)_2-N(-(CH_2)_2)-(2\text{-pyrimidinyl})$	base	207.7
38	Cl	$(CH_2)_2-N(-(CH_2)_2)-[2,3-(CH_3)_2-C_6H_3]$	base	164.6
39	Cl	$(CH_2)_2-N(-(CH_2)_2)-(3-CH_3-C_6H_4)$	base	140.1
40	Cl	$CH_2-CH(CH_3)-N(-(CH_2)_2)-(2-Cl-C_6H_4)$	base	118.2

41	Cl	$(CH_2)_2$-N-(4-$C_2H_5OC(O)$-C_6H_4) $(CH_2)_2$	base	200.6
42	Cl	$(CH_2)_2$-N-[2,4-$(CH_3)_2$-C_6H_3] $(CH_2)_2$	base	155.8
43	Cl	CH_2-CH(CH_3)-N-(4-CH_3-C_6H_4) $(CH_2)_2$	base	124.4
44	Cl	$(CH_2)_2$-N-(2-CH_3O,5-CF_3-C_6H_3) $(CH_2)_2$	base	160.0
45	Cl	$(CH_2)_2$-N-CH(C_6H_5)$_2$ $(CH_2)_2$	base	156.4
46	Cl	CH_2-CH(CH_3)-N-(3-CH_3-C_6H_4) $(CH_2)_2$	base	114.8
47	Cl	$(CH_2)_2$-N-(3-F-C_6H_4) $(CH_2)_2$	base	153.1
48	Cl	$(CH_2)_2$-N-(3-CN-2-pyridinyl) $(CH_2)_2$	base	177.3
49	Cl	$(CH_2)_2$-N-C_6H_4-C(O)-(4-Cl-C_6H_4) $(CH_2)_2$	base	262.5
50	Cl	CH_2-CH(CH_3)-N-(4-Cl-C_6H_4) $(CH_2)_2$	base	161.3
51	Cl	$(CH_2)_2$-N-[3,4-$(CH_3O)_2$-C_6H_3] $(CH_2)_2$	base	149.5
52	Cl	CH_2-CH(CH_3)-N-C_6H_5 $(CH_2)_2$	base	145.9
53	Cl	$(CH_2)_2$-N-(4-OH-C_6H_4) $(CH_2)_2$	base	203.5
54	Cl	$(CH_2)_2$-CH-NH-C_6H_5 $(CH_2)_2$	base	149.6
55	Cl	$(CH_2)_2$-N-(3,5-Cl_2-C_6H_3) $(CH_2)_2$	base	167.2
56	Cl	$(CH_2)_2$-N-[3,5-$(CH_3)_2$-C_6H_3] $(CH_2)_2$	base	164.7

57	Cl	$CH_2-CH(CH_2)_3-NH-[2,3-(CH_3)_2-C_6H_3]$	HCl	218.0
58	Cl	$CH_2-CH(CH_2)_2-NH-(3-CH_3-C_6H_4)$	base	161.9
59	Cl	$CH_2-CH(CH_2)_3-NH-C_6H_5$	HCl	142.2
60	Cl	$(CH_2)_3-N(CH_2)_2-(3-Cl-C_6H_4)$	base	123.0
61	Cl	$CH_2-CH(CH_2)_3-NH-(3-CH_3-C_6H_4)$	HCl	176.5
62	Cl	$(CH_2)_2-N(CH_2)_2-(2,4-Cl_2-C_6H_3)$	base	185.2
63	Cl	$(CH_2)_3-N(CH_2)_2-[2,3-(CH_3)_2-C_6H_3]$	base	118.8
64	Cl	$(CH_2)_3-N(CH_2)_2-(3,5-Cl_2-C_6H_3)$	base	174.9
65	Cl	$(CH_2)_2-C(C_6H_5)(CH_2)_2-C(O)-NH-C_6H_5$	base	224.4
66	Cl	$(CH_2)_2-CH(CH_2)_2-N(CH_3)(3-CH_3C_6H_4)$	base	136.5
67	Cl	$(CH_2)_2-C(OH)(CH_2)_2-CH_2-(4-Cl-C_6H_4)$	base	172.9
68	Cl	$(CH_2)_2-C(OCH_3)(CH_2)_3-C_6H_5$	base	147.6

69	Cl		HCl	194.5
70	Cl		base	221.8
71	Cl		base	95.2
72	Cl		base	199.6
73	Cl		base	167.9
74	Cl		base	120.9
75	Cl		base	80.4
76	Cl		base	119.0
77	Cl		base	120.8
78	Cl		base	178.7
79	Cl		base	140.4

80	Cl		base	163.2
81	Cl		base	148.0
82	Cl		base	237.8
83	Cl		base	126.0
84	Cl		HCl	173.8
85	Cl		base	127.9
86*	Cl		base	163.8
87	Cl		base	162.7
88	Cl		base	152.0
89	Cl		base	207.7
90	Cl		base	156.4

* cis form

91	Cl		base	118.9
92	Cl		base	206.0
93	Cl		base	147.0
94	Cl		base	137.5
95	Cl		base	134.7
96	Cl		base	134.7
97*	Cl		base	154.0
98	Cl		base	153.3
99*	Cl		base	160.5
100*	Cl		base	148.1
101	Cl		base	182.7

102	Cl		base	156.8
103	Cl		base	175.0
104	Cl		base	201.8
105	Cl		HCl	200
106	Cl		base	208.4
107	Cl		base	169.4
108	Cl		base	105.1
109	Cl		base	161.5
110	Cl		base	123.1
111	Cl		base	156.6

112	Cl	$(CH_2)_2-C(=CH-CH_2)-$(1-naphthalenyl)		base	138.4
113	$CH_3O-C(=O)$	$(CH_2)_2-N(-(CH_2)_2)-(3-CH_3-C_6H_4)$		base	185.5
114	Cl	$(CH_2)_2-C(OH)(-(CH_2)_2)-[4-CH(CH_3)_2-C_6H_4]$		base	136.5
115	Cl	$(CH_2)_2-C(OH)(-(CH_2)_2)-(CH_2)_4-C_6H_5$		base	106.2
116	Cl	$(CH_2)_2-C(OH)(-(CH_2)_2)-(CH_2)_2-C_6H_5$		base	147.3
117	Cl	$(CH_2)_2-C(OH)(-(CH_2)_2)-$(2-naphthalenyl)		base	196.1
118	Cl	$(CH_2)_2-N(-(CH_2)_2)-(4-NO_2-C_6H_4)$		$HCl.1/2H_2O$	266.7
119	Cl	$(CH_2)_2-C(OH)(-(CH_2)_2)-(4-CH_3O-C_6H_4)$		base	173.7
120	NC	$(CH_2)_2-N(-(CH_2)_2)-(3-CH_3-C_6H_4)$		base	179.8
121	Cl	$(CH_2)_2-C(=CH-CH_2)-(4-Cl-C_6H_4)$		base	204.5
123	Cl	$(CH_2)_2-C(OH)(-(CH_2)_2)-CH_3$		base	125.1

124	CH_3OOC	$(CH_2)_2-C(=CH_2)-CH_2-(3-CH_3-C_6H_4)$	base	159.6
125		$(CH_2)_2-C(=CH_2)-CH_2-(3-CH_3-C_6H_4)$	base	164.8
126	Cl	$(CH_2)_2-N(-(CH_2)_2)-(1\text{-naphthalenyl})$	base	156.6
127	CH_3OOC	$(CH_2)_2-C(OH)(-(CH_2)_2)-(3-CH_3-C_6H_4)$	base	-
128	Cl	$CH_2-C(=CH_2)-CH_2-(2\text{-thienyl})$	base	210.7
129	I	$(CH_2)_2-C(=CH_2)-CH_2-(3-CH_3-C_6H_4)$	base	145.4
130	CN	$(CH_2)_2-C(=CH_2)-CH_2-(3-CH_3-C_6H_4)$	base	138.0
131	Cl	$(CH_2)_2-C(OH)(-(CH_2)_2)-(2\text{-pyridinyl})$	base	-
132	Cl	$(CH_2)_2-C(=CH_2)-CH_2-(2\text{-pyridinyl})$	base	-
133	Cl	$(CH_2)_2-C(=CH_2)-CH_2-CH_3$	base	-
134	Cl	$(CH_2)_2-C(=CH_2)-CH_2-(CH_2)_3-CH_3$	base	-

In a similar manner there was also prepared: ethyl 4-(6-chloro-5-methyl-3-pyridazinyl)-1-piperazinecarboxylate; mp. 132.2 °C (compound 135).

Example 26

A mixture of 5 parts of 1-(3-methylphenyl)piperazine dihydrochloride, 10.6 parts of sodium carbonate

and 180 parts of N , N -dimethylformamide was stirred for 1 hour at 65° C. Then there were added 7.2 parts of 3,6-dibromopyridazine and the whole was stirred overnight at about 65° C. The reaction mixture was pour d into ice water. The product was filter d off and dissolved in dichloromethan . The solution was washed twice with water, dried, filtered and evaporated. The residue was crystallized from ethanol. The product was filtered off and dried, yielding 4.1 parts (61.5%) of 3-bromo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 145.7° C (compound 136).

In a similar manner there were also prepared:

3-bromo-6-[4-(2,3-dimethylphenyl)-1-piperazinyl]pyridazine; mp. 166.7° C (compound 137);

3-bromo-6-[4-(3-chlorophenyl)-1-piperazinyl]pyridazine; mp. 158.7° C (compound 138);

3-bromo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]pyridazine; mp. 154.3° C (compound 139);

3-bromo-6-[4-(2-methoxyphenyl)-1-piperazinyl]pyridazine; mp. 164.8° C (compound 140);

3-bromo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]pyridazine monohydrochloride; mp. 222.5° C (compound 141);

3-bromo-6-[3,6-dihydro-4-[3-(trifluoromethyl)phenyl]-1(2 H)-pyridinyl]-pyridazine; mp. 130.6° C (compound 142);

1-(6-bromo-3-pyridazinyl)-4-(3-chlorophenyl)-hexahydro-1 H -1,4-diazepine; mp. 148.8° C (compound 143);

3-bromo-6-[4-(3-bromophenyl)-1-piperazinyl]pyridazine; mp. 179.8° C (compound 144); and

3-bromo-6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-pyridazine; mp. 127.1° C (compound 145);

Example 27

A mixture of 4.5 parts of 3,6-dichloropyridazine, 4.9 parts of N -[3-(trifluoromethyl)phenyl]-3-piperidinamine, 6.4 parts of sodium carbonate and 180 parts of N , N -dimethylformamide was stirred overnight at about 65° C. The reaction mixture was poured into ice water and the product was extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2-propanol. The product was filtered off (the filtrate was set aside) and dried, yielding 1.2 parts (16.8%) of 1-(6-chloro-3-pyridazinyl)-N -[3-(trifluoromethyl)phenyl]-3-piperidinamine; mp. 92.6° C (compound 146). The filtrate, which was set aside, was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 2.6 parts (32.9%) of 1-(6-chloro-3-pyridazinyl)-N -[3-(trifluoromethyl)-phenyl]-3-piperidinamine monohydrochloride; mp. 173.5° C (compound 147).

Example 28

A mixture of 3 parts of 3,6-dichloropyridazine, 6.1 parts of N -[3-(trifluoromethyl)phenyl]-4-piperidinamine dihydrobromide, 6.4 parts of sodium carbonate and 180 parts of N , N -dimethylacetamide was stirred for 24 hours at 60° C. After cooling to room temperature, the reaction mixture was poured onto water. The product was extracted with methylbenzene. The extract was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (97:3 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 2.5 parts (47%) of 1-(6-chloro-3-pyridazinyl)-N -[3-(trifluoromethyl)phenyl]-4-piperidinamine; mp. 117.9° C (compound 148).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:



No.	R^1	R^2	R^3	A	Salt or base	mp. in °C
149	Cl	H	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(4-Cl-C_6H_4)	base	209.7
150	Cl	H	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(2-Cl-C_6H_4)	base	184.7
151	Cl	H	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(3-CH_3O-C_6H_4)	base	127.0
152	Cl	H	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(4-F-C_6H_4)	base	197.4
153	Cl	H	H	$(CH_2)_2$-N(-$(CH_2)_2$)-(3,4-Cl_2-C_6H_3)	base	160.5
154	Cl	H	H	$(CH_2)_2$-N(-$(CH_2)_2$)-[2,6-$(CH_3)_2$-C_6H_3]	base	124.4
155	Cl	-CH=CH-CH=CH-		$(CH_2)_2$-N(-$(CH_2)_2$)-[2,3-$(CH_3)_2$-C_6H_3]	base	209.2
156	Cl	-CH=CH-CH=CH-		$(CH_2)_2$-N(-$(CH_2)_2$)-(2-CH_3O-C_6H_4)	base	178.6
157	Cl	-CH=CH-CH=CH-		$(CH_2)_2$-N(-$(CH_2)_2$)-C_6H_5	base	170.2

158	Cl	-CH=CH-CH=CH-		$(CH_2)_2$-N-(3-CF_3-C_6H_4) $(CH_2)_2$	base	167.2
159	Cl	-CH=CH-CH=CH-		$(CH_2)_2$-N-(3-Cl-C_6H_4) $(CH_2)_2$	base	167.0
160	Cl	-CH=CH-CH=CH-		$(CH_2)_2$-N-(3-CH_3-C_6H_4) $(CH_2)_2$	base	135.6
161	Cl	-CH=CH-CH=CH-		$(CH_2)_2$-N-(3,5-Cl_2-C_6H_3) $(CH_2)_2$	base	225.6
162	Cl	H	H	$(CH_2)_2$-C(OH)-(3,4-Cl_2-C_6H_3) $(CH_2)_2$	base	196.3
163	Cl	H	H	$(CH_2)_2$-C(C(O)O-CH_2CH_3)-(3-Cl-C_6H_4) $(CH_2)_2$	base	155.5
164	Cl	H	H	$(CH_2)_2$-C(C(O)-NH_2)-NH-(3-CH_3-C_6H_4) $(CH_2)_2$	base	195.1
165	Cl	H	H	$(CH_2)_2$-N-(3-Br-C_6H_4) $(CH_2)_2$	base	157.1
166	Cl	H	H	$(CH_2)_2$-C(O-$(CH_2)_3$-(1-piperidinyl))-C_6H_5 $(CH_2)_2$	base	137.1
167	Cl	H	H	$(CH_2)_2$-C($(CH_2)_2$-CH_3)-C_6H_5 $(CH_2)_2$	base	136.8

168	Cl	H	H	$CH_2-CH(-(CH_2)_2)-(3-CF_3-C_6H_4)$	1/2 $(COOH)_2$	155.2
169	Cl	-CH=CH-CH=CH-		$(CH_2)_2-N(-(CH_2)_2)-(2,3-Cl_2-C_6H_3)$	base	218.5
170	Cl	H	H	$(CH_2)_3-N(-(CH_2)_2)-C_6H_5$	base	132.7
171	Cl	H	H	$(CH_2)_2-CH(-(CH_2)_2)-CO-CH_2-C_6H_5$	base	130.2
172	Cl	H	H	$(CH_2)_3-CH(-CH_2)-(3-CF_3-C_6H_4)$	base	121.7
173	Cl	H	H	$(CH_2)_2-CH(-(CH_2)_2)-CH_2-CO-(3-F-C_6H_4)$	base	156.2
174	Cl	H	H	$(CH_2)_2-C(OH)(-CH_2)-(3-Cl-C_6H_4)$	base	170.4
175	Cl	H	H	$(CH_2)_3-N(-(CH_2)_2)-(3-CF_3-C_6H_4)$	base	144.7
176	Cl	H	H	$CH_2-C(OH)(-(CH_2)_3)-C_6H_5$	base	138.0
177	Cl	H	H	$CH_2-C(OH)(-(CH_2)_3)-(3-CF_3-C_6H_4)$	base	95.0
178	Cl	H	H	$(CH_2)_3-C(H)(-CH_2)-C_6H_5$	base	107.5
179	Cl	H	H	$(CH_2)_3-C(H)(-CH_2)-(3-CH_3-C_6H_4)$	HBr 1/2 $CH_3-CHOH-CH_3$	193.0

180	Cl	H	H	$(CH_2)_3-C(OH)(CH_2)-(3-CH_3-C_6H_4)$	base	104.4
181	Cl	H	H	$(CH_2)_3-C(OH)(CH_2)-(2\text{-thienyl})$	base	154.0
182	Cl	H	H	$(CH_2)_3-C(OH)(CH_2)-(3-Cl-C_6H_4)$	base	121.7
183	Cl	H	H	$(CH_2)_3-C(H)(CH_2)-(3-F-C_6H_4)$	base	91.5
184	Cl	H	H	$(CH_2)_3-C(OH)(CH_2)-(3-F-C_6H_4)$	base	119.3
185	Br	H	H	$(CH_2)_2-N(-(CH_2)_2)-(CH_2)_3-C_6H_5$	HC(=CH-COOH)-COOH	197.3
186	Cl	H	H	$(CH_2)_3-C(OH)(CH_2)-[2,3-(CH_3)_2-C_6H_3]$	base	183.7
187	Cl	H	H	$(CH_2)_3-C(H)(CH_2)-[2,3-(CH_3)_2-C_6H_3]$	base	115.7
188	Cl	H	H	$(CH_2)_2-C(OH)(CH_2)-(3-CH_3-C_6H_4)$	base	164.4
189	Cl	H	H	$(CH_2)_2-CH=C(CH_2)-(3-CH_3-C_6H_4)$	base	94.6

190	Cl	H	H	$(CH_2)_2$-CH(-$(CH_2)_2$)-(2-thienyl)	base	127.0
191	Cl	H	H	$(CH_2)_3$-C(OH)H-C(CH_2)-(3-OCH_3-C_6H_4)	HCl	193.8
192	Cl	H	H	$(CH_2)_3$-CH-C(CH_2)-(3-OCH_3-C_6H_4)	base	102.1
193	Cl	H	H	$(CH_2)_3$-C(OH)H-C(CH_2)-(4-Cl,3-CF_3-C_6H_3)	base	129.8
194	Cl	H	H	$(CH_2)_3$-CH=C(CH_2)-(3-F-C_6H_4)	base	121.5
195	Cl	H	H	$(CH_2)_2$-C(OH)-C(CH_2)-(3-F-C_6H_4)	base	138.4
196	Cl	H	H	$(CH_2)_2$-CH-C(CH_2)-(3-CH_3-C_6H_4)	base	74.7
197	Cl	H	H	$(CH_2)_2$-C(OH)H-C(CH_2)-(4-Cl,3-CF_3-C_6H_3)	base	168.0
198	Cl	H	H	$(CH_2)_2$-C(OH)H-C(CH_2)-(3-OCH_3-C_6H_4)	base	115.1
199	Cl	H	H	$(CH_2)_2$-C(OH)H-C(CH_2)-(2-thienyl)	base	179.5

200	Cl	H	H	$(CH_2)_2$-CH(-$(CH_2)_2$)-NH-$COOC_2H_5$	bas	157.9
201	Cl	H	H	$(CH_2)_2$-CH(CH_2)-(2-thienyl)	base	119.3

Example 29

A mixture of 5.2 parts of 3,6-diiodopyridazine, 3.5 parts of 1-[3-(trifluoromethyl)phenyl]piperazine, 3.2 parts of sodium carbonate and 90 parts of N , N -dimethylacetamide was stirred and heated overnight at 70 °C. The reaction mixture was poured onto water. The precipitated product was filtered off and crystallized from 2-propanol, yielding 3.2 parts (48%) of 3-iodo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-pyridazine; mp. 144.6 °C (compound 202).

In a similar manner there were also prepared:

3-iodo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 163.1 °C (compound 203);

3-[4-(3-chlorophenyl)-1-piperazinyl]-6-iodopyridazine; mp. 165.0 °C (compound 204):

3-[4-(2,3-dimethylphenyl)-1-piperazinyl]-6-iodopyridazine; mp. 179.4 °C (compound 205); and

3-iodo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]pyridazine; mp. 106.8 °C (compound 206).

Example 30

A mixture of 4.6 parts of 1-[3-(trifluoromethyl)phenyl]piperazine, 6.4 parts of sodium carbonate and 160 parts of 4-methyl-2-pentanone was distilled azeotropically to dry. 3.3 Parts of 3,6-dichloropyridazine were added and the whole was stirred and refluxed for 48 hours using a water separator. After cooling, water was added and the product was extracted with dichloromethane. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2-propanol, yielding 2.6 parts (37.9%) of 3-chloro-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]pyridazine; mp. 149.4 °C (compound 207).

Example 31

To a stirred solution of 7.5 parts of 3,6-dichloropyridazine in 75 parts of N , N -dimethylformamide was added dropwise a solution of 8 parts of ethyl 1-piperazinecarboxylate and 5.6 parts of N , N -diethylethanamine in 25 parts of N , N -dimethylformamide. Upon completion, the whole was stirred overnight at a temperature of about 50 °C. After cooling, the reaction mixture was poured onto water and the product was extracted with trichloromethane. The organic layer was dried, filtered and evaporated. The residue was crystallized from 2-propanol, yielding 3.6 parts of ethyl 4-(6-chloro-3-pyridazinyl)-1-piperazinecarboxylate; mp. 123.8 °C (compound 208).

Example 32

A mixture of 3.2 parts of 3-chloro-6-(methylsulfonyl)pyridazine, 3 parts of 1-(3-methylphenyl)piperazine, 2 parts of N , N -diethylethanamine and 180 parts of benzene was stirred for 24 hours at reflux. The reaction mixture was evaporated. Water was added to the residue. The precipitated product was filtered off, washed with water and dissolved in trichloromethane. The solution was dried, filtered and evaporated. The residue was crystallized from methanol. The product was filtered off and dried, yielding 5 parts (89%) of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-(methylsulfonyl)pyridazine; mp. 201 °C (compound 209).

In a similar manner there were also prepared:
3-[4-(3-methylph nyl)-1-piperazinyl]-6-(methylsulfinyl)pyridazine; mp. 146.9° C (compound 210);
3-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-(methylsulfonyl)pyridazine; mp. 179.8° C (compound 211); and
3-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-(methylsulfinyl)pyridazine; mp. 131.0° C (compound 212).

Example 33

A mixture of 3.3 parts of 3,6-dichloropyridazine, 3.3 parts of 1-(2-pyridinyl)piperazine, 1.5 parts of sodium hydrogencarbonate and 120 parts of ethanol was stirred and refluxed over weekend. The reaction mixture was evaporated. Water was added to the residue and the product was extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and tetrahydrofuran, yielding 2.5 parts (45.3%) of 3-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]pyridazine; mp. 194.7° C (compound 213).

Example 34

A mixture of 3.2 parts of 3-chloro-6-(methylthio)pyridazine, 3.14 parts of 1,2,3,6-tetrahydro-4-(3-methylphenyl)pyridine hydrochloride, 5.3 parts of sodium carbonate and 80 parts of 1-butanol was stirred for 48 hours at reflux temperature. The reaction mixture was evaporated. Water was added. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 0.8 parts (18%) of 3-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-(methylthio)pyridazine; mp. 129.8° C (compound 214).

Example 35

To a stirred solution of 300 parts of hexahydro-1 H -1,4-diazepine in 900 parts of methylbenzene were added 75 parts of 3,6-dichloropyridazine. The whole was stirred and refluxed for 4 hours. The reaction mixture was evaporated. Water was added to the residue. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was converted into the hydrochloride salt in 2-propanol and ethanol. The salt was filtered off and dried, yielding 28 parts (22%) of 1-(6-chloro-3-pyridazinyl)-hexahydro-1 H -1,4-diazepine monohydrochloride (compound 215).
In a similar manner there was also prepared:
1-(6-chloro-5-methyl-3-pyridazinyl)hexahydro-1 H -1,4-diazepine as a residue (compound 216).

Example 36

A mixture of 3.9 parts of 3,6-dichloro-4,5-dimethylpyridazine, 4.2 parts of 1-(2,3-dimethylphenyl)-piperazine and 2.94 parts of potassium carbonate was stirred and heated for 4 hours in an oil bath at 190° C. After cooling, the mixture was taken up in water and trichloromethane. The organic layer was separated, dried, filtered and evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 2 parts (30%) of 3-chloro-6-[4-(2,3-dimethylphenyl)-1-piperazinyl]-4,5-dimethylpyridazine; mp. 194.5° C (compound 217).
In a similar manner there were also prepared:
3-chloro-4,5-dimethyl-6-[4-(3-m thylphenyl)-1-piperazinyl]pyridazine; mp. 172.9° C (compound 218); and
4-(3-methylphenyl)-1-(6-methyl-3-pyridazinyl)-4-piperidinol; mp. 131.5° C (compound 219).

Example 38

A mixture of 3.5 parts of N -(6-chloro-3-pyridazinyl)acetamide, 3.6 parts of 1-(3-methylphenyl)piperazine and 2.8 parts of potassium carbonate was stirred for 7 hours in an oil bath at 160 °C. After cooling, trichloromethane and water were added. The layers were separated. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (97:3 by volume) as eluent. The second fraction was collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in 2-propanol and 2-propanone. The salt was filtered off and dried, yielding 0.5 parts (6.6%) of 6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazinamine dihydrochloride; mp. 178.5 °C (compound 220).

Example 38

A mixture of 4 parts of 6-chloro-3-(4-ethylphenoxy)pyridazine and 6 parts of 1-(3-methylphenyl)-piperazine was stirred and heated for 3 hours in an oil bath at 110 °C. The whole was allowed to stand overnight. Concentrate ammonium hydroxide and trichloromethane were added. The precipitate was filtered off and the filtrate was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 1.7 parts (27%) of 3-(4-ethylphenoxy)-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 106.6 °C (compound 221).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

3-methyl-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 152.9 °6 (compound 222); and

3-[4-(3-methylphenyl)-1-piperazinyl]-6-(methylthio)pyridazine; mp. 145.0 °6 (compound 223).

Example 39

A mixture of 22 parts of ethyl 4-(6-chloro-5-methyl-3-pyridazinyl)-1-piperazinecarboxylate, 28 parts of potassium hydroxide and 160 parts of 1-butanol was stirred overnight at reflux temperature. The reaction mixture was evaporated. Water was added. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. 2,2'-Oxybispropane was added. The product was filtered off and dried, yielding 17 parts (100%) of 3-chloro-4-methyl-6-(1-piperazinyl)pyridazine (compound 224).

Example 40

A mixture of 6 parts of ethyl [1-(6-chloro-3-pyridazinyl)-4-piperidinyl]carbamate and 60 parts of concentrate hydrochloric acid was stirred and refluxed for 24 hours. The reaction mixture was evaporated, Water was added and the whole was treated with concentrate ammoniun hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated, yielding 3.8 parts (82%) of 1-(6-chloro-3-pyridazinyl)-4-piperidinamine; mp. 260 °C. (dec.) (compound 225).

Example 41

A mixture of 3.6 parts of 3-chloro-6-(1-piperazinyl)pyridazine monohydrochloride, 5.3 parts of sodium carbonate and 90 parts of N , N -dimethylacetamide was stirred for a while at 60 °C. Then there were added 3 parts of (3-bromopropyl)benzene and the whole was stirred overnight at 60 °C. The reaction mixture was poured into water. The product was filtered off and converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 3.2 parts (60%) of 3-chloro-6-[4-(3-phenylpropyl)-1-piperazinyl]-pyridazine monohydrochloride; mp. 207.3 °C (compound 226)

In a similar manner there were also prepared:

3-chloro-4-methyl-6-[4-(3-phenylpropyl)-1-piperazinyl]pyridazine monohydrochloride 1-butanol(1:1)-.monohydrate;mp. 187.2 °C (compound 227);

3-methoxy-6-[4-(3-phenylpropyl)-1-piperazinyl]pyridazine; mp. 78.4 °C (compound 228);

3-[4-(3-phenylpropyl)-1-piperazinyl]pyridazine dihydrochloride. monohydrate; mp. 209.0 °C (compound 229); and

1-acetyl-4-(6-chloro-3-pyridazinyl)piperazine; mp. 153.6° C (compound 230).

Example 42

A mixture of 3 parts of 3-chloro-6-(1-piperazinyl)pyridazine, 2 parts of benzeneacetylaldehyde 1 part of a solution of thiophene in methanol 4% and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of platinum-on-charcoal catalyst 5%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 1.5 parts (33%) of 3-chloro-6-[4-(2-phenylethyl)-1-piperazinyl]pyridazine; mp. 140.0° C (compound 231).

In a similar manner there were also prepared: 3-(4-butyl-1-piperazinyl)-6-chloropyridazine (E)-2-butenedioate(1:1); mp. 188.2° C (compound 232);

3-chloro-6-(4-cyclohexyl-1-piperazinyl)pyridazine; mp. 187.2° C (compound 233); and

1-(6-chloro-3-pyridazinyl)-N -(phenylmethyl)-4-piperidinamine; mp. 93.8° C (compound 234).

Example 43

A mixture of 4 parts of 1-(6-chloro-3-pyridazinyl)-4-(3-methoxyphenyl)-4-piperidinol, 80 parts of ethanol and 50 parts of a hydrochloric acid solution 6N was stirred for 6 hours at reflux temperature. The reaction mixture was evaporated. Water was added and the whole was treated with concentrate ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 2.5 parts (64%) of 3-chloro-6-[3,6-dihydro-4-(3-methoxyphenyl)-1(2 H)-pyridinyl]pyridazine; mp. 126.4° C (compound 235).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

3-chloro-6-[4-(3-chlorophenyl)-3,6-dihydro-1(2 H)-pyridinyl]-pyridazine; mp. 133.9° C (compound 236);

3-chloro-6-(3,4-dihydro-5-phenyl-1(2 H)-pyridinyl)pyridazine; mp. 146.0° C (compound 237);

3-chloro-6-[3,4-dihydro-5-(3-methylphenyl)-1(2 H)-pyridinyl]pyridazine; mp. 160.0° C (compound 238);

3-chloro-6-[4-(3-fluorophenyl)-3,6-dihydro-1(2 H)-pyridinyl]pyridazine; mp. 124.7° C (compound 239);

3-chloro-6-[4-(2,3-dimethylphenyl)-3,6-dihydro-1(2 H)-pyridinyl]-pyridazine; mp. 144.2° C (compound 240);

3-chloro-6-[4-(3-chlorophenyl)-3,6-dihydro-5-methyl-1(2 H)-pyridinyl]-pyridazine; mp. 88.5° C (compound 241);

3-chloro-6-[3,4-dihydro-5-[3-(trifluoromethyl)phenyl]-1(2 H)-pyridinyl] pyridazine; mp. 163.2° C (compound 242);

3-chloro-6-[3,6-dihydro-5-[3-(trifluoromethyl)phenyl]-1(2 H)-pyridinyl] pyridazine; mp. 112.5° C (compound 243);

3-chloro-6-[5-(3-fluorophenyl)-3,6-dihydro-1(2 H)-pyridinyl]pyridazine; mp. 134.9° C (compound 244);

3-chloro-6-[3,4-dihydro-5-(3-methoxyphenyl)-1(2 H)-pyridinyl]-pyridazine; mp. 129.1° C (compound 245);

3-chloro-6-[5(2,3-dimethylphenyl)-3,4-dihydro-1(2 H)-pyridinyl]-pyridazine; mp. 148.8° C (compound 246);

3-chloro-6-[3,6-dihydro-4-(2-naphthalenyl)-1(2 H)-pyridinyl]pyridazine monohydrochloride hemihydrate; mp. 187.2° C (compound 247);

3-chloro-6-[3-(3-methylphenyl)-2 H -pyrrol-1(5 H)-yl]pyridazine; mp. 198.1° C (compound 248);

3-chloro-6-[2,3-dihydro-4-(3-methylphenyl)-1 H -pyrrol-1-yl]pyridazine; mp. 195.3° C (compound 249);

3-chloro-6-[3,6-dihydro-4-(2-phenylethyl)-1(2 H)-pyridinyl]pyridazine; mp. 104.2° C (compound 250);

3-chloro-6-[5-[4-chloro-3-(trifluoromethyl)phenyl]-3,4-dihydro-1(2 H)-pyridinyl]pyridazine; mp. 140.9° C (compound 251);

3-chloro-6-[3-(3-fluorophenyl)-2,3-dihydro-1 H -pyrrol-1-yl]pyridazine; mp. 213.0° C (compound 252);

3-chloro-6-[3-(3-fluorophenyl)-2,5-dihydro-1 H -pyrrol-1-yl]pyridazine; mp. 228.8° C (compound 253);

3-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-methylpyridazine; mp. 123.4° C (compound 254);

3-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-methoxypyridazine; mp. 116.4° C (compound 255); and

3-butoxy-6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]pyridazine; mp. 97.8° C (compound 256).

Example 44

To a stirred mixture of 80 parts of 1-butanol, 0.4 parts of sodium hydroxide and 0.94 parts of phenol were added 2.2 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine at 60° C. The whole was stirred and refluxed over weekend. The reaction mixture was evaporated. The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 2 parts (64%) of 3-butoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 105.2° C (compound 257).

Example 45

To a stirred sodium methoxide solution, previously prepared starting from 1.6 parts of sodium in 24 parts of methanol, were added 4 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine. The whole was stirred and refluxed for 40 hours. After cooling, 25 parts of water were added. The product was filtered off, washed with water and dissolved in trichloromethane. The organic layer was dried, filtered and evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product was filtered off and dried, yielding 2 parts (50%) of 3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]-pyridazine; mp. 137.1° C (compound 258).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

3-[4-(3-fluorophenyl)-3,4-dihydro-1(2 H)-pyridinyl]-6-methoxypyridazine; mp. 85.2° C (compound 259);

3-[3,6-dihydro-4-(2,3-dimethylphenyl)-1(2 H)-pyridinyl]-6-methoxypyridazine; mp. 110.8° C (compound 260);

1-(6-methoxy-3-pyridazinyl)-4-(3-methylphenyl)-4-piperidinol; mp. 125.6° C (compound 261);

3-[3,4-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-ethoxypyridazine; mp. 84.3° C (compound 262); and

1-(6-butoxy-3-pyridazinyl)-4-(3-methylphenyl)-4-piperidinol; mp. 106.7° C (compound 263).

Example 46

A mixture of 1.9 parts of phenol, 2.9 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine and 2.76 parts of potassium carbonate was stirred and heated for 7 hours in an oil bath at 150° C. After cooling, water was added. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product was filtered off and dried, yielding 2 parts (60%) of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-phenoxypyridazine; mp. 123.4° C (compound 264).

In a similar manner there were also prepared:

3-(4-chlorophenoxy)-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 130.1° C (compound 265); and

3-[4-(3-methylphenyl)-1-piperazinyl]-6-(phenylthio)pyridazine; mp. 135.3° C (compound 266).

Example 47

To a stirred solution of 0.7 parts of sodium in 20 parts of benzenemethanol were added 5.8 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine. The whole was stirred and heated in an oil bath at 180° C. After standing overnight, water was added and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. 2,2'-Oxybispropane was added to the residue. The product was filtered off and crystallized from a mixture of 2-propanol and methanol. The product was filtered off and dried, yielding 3.4 parts (47%) of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-(phenylmethoxy)pyridazine; mp. 159.4° C (compound 267).

In a similar manner there was also prepared:

4-(3-methylphenyl)-1-[6-(phenylmethoxy)-3-pyridazinyl]-4-piperidinol; mp. 124.8° C (compound 268).

Example 48

A mixture of 6.1 parts of 4-(3-methylphenyl)-1-[6-(phenylmethoxy)-3-pyridazinyl]-4-piperidinol and 250

parts of 2-methoxyethanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was boiled in 2-propanol. The product was filt red off and dried, yielding 4.5 parts (97%) of 6-[4-hydroxy-4-(3-methylphenyl)-1-piperidinyl]-3-pyridazinol; mp. 264.6° C (compound 269).

A mixture of 2.9 parts of 6-[4-hydroxy-4-(3-methylphenyl)-1-piperidinyl]-3-pyridazinol, 30 parts of a hydrochloric acid solution 6N and 24 parts of ethanol was stirred for 2 hours at reflux temperature. The reaction mixture was evaporated. Crushed ice was added and the whole was treated with concentrate ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product was filtered off and dried, yielding 2 parts (75%) of 6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-3-pyridazinol; mp. 179.0° C (compound 270).

Example 49

A mixture of 6 parts of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-(phenylmethoxy)pyridazine and 60 parts of concentrate hydrochloric acid was stirred and refluxed for 3 hours. The whole was allowed to stand overnight and treated with concentrate ammonium hydroxide. The product was filtered off, washed with water and dissolved in trichloromethane. The organic layer was dried, filtered and evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product was filtered off and dried, yielding 4.5 parts (98%) of 6-[4-(3-methylphenyl)-1-piperazinyl]-3-(2 H)-pyridazinone; mp. 209.8° C (compound 271).

Example 50

A mixture of 7.3 parts of 3-chloro-6-[4-(4-methoxyphenyl)-1-piperazinyl]pyridazine, 2 parts of calcium oxide and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated. The residue was crystallized from 2-propanol, yielding 4.1 parts (63.2%) of 3-[4-(4-methoxyphenyl)-1-piperazinyl]pyridazine; mp. 133.4° C (compound 272).

Example 51

A mixture of 5.8 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine and 3 parts of thiourea was stirred for 3 hours in an oil bath at 165° C. After cooling, there were added 150 parts of a sodium hydroxide solution 0.5N. The whole was stirred and refluxed for 15 minutes. It was filtered while hot and the filtrate was neutralized with acetic acid. The product was filtered off, washed with water and separated by column chromatography over silica gel using a mixture of trichloromethane and methanol (98.5:1.5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of ethanol and tetrahydrofuran. The product was filtered off and dried, yielding 1.3 parts (22.7%) of 6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazinethiol; mp. 174.2° C (compound 273).

Example 52

To a stirred solution of 0.92 parts of sodium in 8 parts of methanol were added 45 parts of benzene. Methanol was distilled off and then 6.2 parts of methyl 6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazinecarboxylate and 3.5 parts of ethyl acetate in 45 parts of b nzene were added. The whole was stirred and refluxed overnight. The r action mixture was evaporated. 100 Parts of water were added. The mixture was acidified with 24 parts of concentrate hydrochloric acid, boiled for 2 hours, cooled and treated with sodium hydrogen carbonate. The product was filt red off, washed with water and dissolv d in trichloromethane. Th solution was dried, filtered and evaporated. The residue was purified by column chromatography over silica

gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product was filtered off and dried, yielding 3 parts (51%) of 1-[6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazinyl]ethanone; mp. 135.9 °C (compound 274).

In a similar manner there were also prepared:

1-[6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-3-pyridazinyl]-ethanone; mp. 115.0 °C (compound 275).

C. Pharmacological examples.

Example 53

In order to illustrate the useful anti-viral properties of the compounds of the present invention a number of such compounds were tested in the previously described Rhinovirus Cythopatic Effect Test. These compounds together with the results of the test are gathered in the following table.

Compound No.	lowest concentration in µg/ml
5	10
8	10
29	0.4
207	0.4
149	0.4
213	2
34	0.08
35	2
36	0.4
37	2
40	0.016
41	0.4
44	0.4
48	10
10	2
136	0.003
26	0.4
11	2
25	2
15	2
16	10

18	0.4
21	2
56	0.4
57	2
58	0.016
257	10
22	0.08
24	2
146	0.4
23	0.016
60	0.016
61	0.08
148	0.08
63	0.016
64	0.4
203	0.003
161	10
66	2
67	10
69	0.4
218	0.4
165	0.08
166	10
77	0.08
168	0.003
170	2
80	0.4
204	0.003
266	10
83	2
171	10
202	0.016
84	0.016

172	2
173	2
258	0.0006
142	0.016
143	0.0006
174	2
86	10
28	0.0006
175	0.0006
88	0.003
89	0.4
90	0.016
91	0.4
236	0.016
93	0.08
96	0.4
238	2
101	0.4
104	2
222	0.08
223	0.08
241	0.016
145	0.003
231	10
112	0.08
210	2
113	10
209	10
247	0.4
274	10
120	2
250	0.4
273	0.08
259	0.08

126	2
212	2
275	2

D. Composition Examples.

"Active ingredient" (A.I.) as used throughout the following examples relates to a compound of formula (I), a possible stereochemically isomeric form or pharmaceutically acceptable acid addition salt thereof.

Example 54 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 liters of 2-hydroxypropanoic acid and 1.5 liters of the polyethylene glycol at 60-80° C. After cooling to 30-40° C there were added 35 liters of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 liters of purified water and while stirring there were added 2.5 liters of cocoa flavor and polyethylene glycol q.s. to a volume of 50 liters, providing an oral drop solution comprising 10 milligrams of the A.I. per milliliter. The resulting solution was filled into suitable containers.

Example 55 : ORAL SOLUTION

9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 liters of boiling purified water. In 3 liters of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter solution was combined with the remaining part of the former solution and 12 liters 1,2,3-propanetriol and 3 liters of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were dissolved in 0.5 liters of water and 2 milliliters of raspberry and 2 milliliters of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 liters providing an oral solution comprising 20 milligrams of the active ingredient per teaspoonful (5 milliliters). The resulting solution was filled in suitable containers.

Example 56 : CAPSULES

20 Grams of the A.I., 6 grams sodium lauryl sulfate, 56 grams starch, 56 grams lactose, 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelating capsules, comprising each 20 milligrams of the active ingredient.

Example 57 : FILM-COATED TABLETS

Preparation of tablet core

A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in about 200 milliliters of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose and 15 grams hydrogenated vegetabl oil. The whole was

mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 milligrams of the active ingredient.

Coating

To a solution of 10 grams methyl cellulose in 75 milliliters of denaturated ethanol there was added a solution of 5 grams of ethyl cellulose in 150 milliliters of dichloromethane. Then there were added 75 milliliters of dichloromethane and 2.5 milliliters 1,2,3-propanetriol. 10 Grams of polyethylene glycol was molten and dissolved in 75 milliliters of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 milliliters of concentrated colour suspension (Opaspray K-1-2109) and the whole was homogenated.

The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 58 : INJECTABLE SOLUTION

1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 liters of boiling water for injection. After cooling to about 50° C there were added while stirring 4 grams lactic acid, 0.05 grams propylene glycol and 4 grams of the A.I. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 liter volume, giving a solution of 4 milligrams A.I. per milliliters. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

Example 59 : SUPPOSITORIES

3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 milliliters polyethylene glycol 400. 12 Grams surfactant and triglycerides q.s. ad 300 grams were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured onto moulds at a temperature of 37-38° C to form 100 suppositories each containing 30 milligrams of the active ingredient.

Claims

1. The use for the manufacture of a medicament for treating viral diseases of a compound of formula



(I),

a pharmaceutically acceptable acid-addition salt and/or a possible stereochemically isomeric form and/or a possible tautomeric form thereof, wherein

R^1 is a member selected from the group consisting of hydrogen, halo, 1 H -imidazol-1-yl, C_{1-6}alkyloxy, aryloxy, C_{1-6}alkylthio, arylthio, hydroxy, mercapto, amino, C_{1-6}alkylsulfinyl, C_{1-6}alkylsulfonyl, cyano, C_{1-6}-alkyloxycarbonyl, C_{1-6}alkylcarbonyl, and C_{1-6}alkyl; wherein aryl in the definition of R^1 is phenyl optionally substituted with up to three substituents each independently selected from halo, nitro and C_{1-6}alkyl;

R^2 and R^3 are, each independently, members selected from the group consisting of hydrogen and C_{1-6}alkyl, or R^2 and R^3 combined may form a bivalent radical of formula -CH=CH-CH=CH-;

A is a bivalent radical of formula:



wherein one of the hydrogen atoms within the radical C_mH_{2m}·$C_{m-1}H_{2(m-1)}$ or C_nH_{2n} may be replaced by C_{1-6}alkyl or aryl; said aryl being phenyl optionally substituted with up to three substituents each independently selected from halo;

m and n are, each independently, integers of from 1 to 4 inclu sive, the sum of m and n being 3, 4 or 5;

R^4 is a member selected from the group consisting of hydrogen; C_{1-6}alkyl; aryl; thiazolyl; pyrimidinyl; quinolinyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; Ar^1C_{1-6}alkyl; diphenyl C_{1-6}alkyl; phenyl being substituted with Ar^2carbonyl; pyridinyl, being optionally substituted with cyano or C_{1-6}alkyl; cyclohexyl and cyclohexenyl both being optionally substituted with up to two substituents independently selected from the group consisting of cyano and Ar^3;

wherein aryl in the definition of R^4 is phenyl, optionally substituted with up to 3 substituents, each independently selected from halo, C_{1-6}alkyl, trifluoromethyl, nitro, C_{1-6}alkyloxy, amino, hydroxy and C_{1-6}alkyloxycarbonyl; and naphtalenyl;

Ar^1 is phenyl optionally substituted with up to 3 substituents each independently selected from C_{1-6}alkyl;

Ar^2 is phenyl optionally substituted with up to 3 substituents each independently selected from halo;

Ar^3 is phenyl optionally substituted with up to 3 substituents each independently selected from halo;

R^5 is hydrogen; C_{1-6}alkyl; aryl; hydroxy; C_{1-6}alkyloxy; Ar^4oxy; C_{1-6}alkyloxy being substituted with morpholine, pyrrolidine or piperidine; amino; (C_{1-6}alkyloxycarbonyl)amino; Ar^5amino; (Ar^6)(C_{1-6}alkyl)-amino; (phenyl C_{1-6}alkyl)amino; (phenyl C_{2-6}alkenyl)amino; (phenyl C_{2-6}alkenyl)(C_{1-6}alkyl)amino; phenylcarbonyloxy;

Ar^4 is phenyl optionally substituted with up to 3 substituents each independently selected from halo and C_{1-6}alkyl;

Ar^5 is phenyl optionally substituted with up to 3 substituents each independently selected from halo, C_{1-6}alkyl, trifluoromethyl;

Ar^6 is phenyl optionally substituted with up to 3 substituents each independently selected from C_{1-6}alkyl;

R^6 is hydrogen; aryl; C_{1-6}alkyl; (C_{1-6}alkylcarbonyl amino) C_{1-6}alkyl, Ar^7C_{1-6} alkyl; Ar^8carbonyl C_{1-6}alkyl; aminocarbonyl; Ar^9carbonyl; phenylaminocarbonyl; (phenyl C_{1-6}-alkyl)carbonyl, C_{1-6}alkyloxycarbonyl; indolyl; pyridinyl; Ar^7 is phenyl optionally substituted with up to 3 substituents each independently selected from halo and C_{1-6}alkyl; Ar^8 is phenyl optionally substituted with up to 3 substituents each independently selected from halo; Ar^9 is phenyl optionally substituted with up to 3 substituents each independently selected from halo and trifluoromethyl;

R^7 and R^8 are, each independently, members selected from the group consisting of hydrogen, C_{1-6}alkyl, aryl, $Ar^{10}C_{1-6}$-alkyl and pyridinyl; wherein Ar^{10} is phenyl optionally substituted with up to 3 substituents each independently selected from halo;

wherein aryl as in the definitions of R^5, R^6, R^7 and R^8 is phenyl, being optionally substituted with up to 3 substituents, each independently selected from the group consisting of halo, C_{1-6}alkyl, trifluoromethyl, nitro, amino, C_{1-6}alkyloxy, hydroxy and C_{1-6}alkyloxycarbonyl; thienyl; and naphthalenyl.

2. The use of a composition comprising a compound of formula (I), a pharmaceutically acceptable acid

addition salt thereof, or a stereoisomer ther of, as defined in claim 1, and a suitable pharmaceutical carrier, for the manufacture of an anti-viral medicament.

3. Th use according to claim 1 or 2 for the manufacture of an anti-Rhinoviral medicament.

4. A compound of formula (I) as defined in claim 1, wherein R^4 is other than 3,3-diphenylpropyl when R^1, R^2 and R^3 are hydrogen radicals and A is a radical of formula (b);



is other than piperidinyl, when R^1 is hydrogen and R^2 and R^3 combined form a bivalent CH=CH-CH=CH radical;

is other than piperidinyl and hexahydro-1 H -azepinyl, when R^1 is halo, R^2 is C_{1-6}alkyl and R^3 is hydrogen; R^4 is other then (dimethoxyphenyl)methyl, (dimethoxyphenyl)-ethyl, α-methyl-phenethyl or (2-methylphenyl)methyl, when R^1 is chloro or methoxy and A is a radical of formula (b) for use as a medicine.

5. A compound of formula (I) as defined in claim 4 for use as an anti-viral medicine.

6. A compound according to claim 4 or 5 wherein A is a bivalent radical of formula (b), wherein R^4 is aryl, pyridinyl, pyrimidinyl, C_{1-6}alkyloxycarbonyl, Ar^1C_{1-6}alkyl, diphenyl C_{1-6}-alkyl, quinolinyl, or wherein A is a bivalent radical of formula (c), wherein R^5 is hydrogen, aryl, Ar^5amino, $(Ar^6)(C_{1-6}$-alkyl)amino, hydroxy, indolyl and R^6 is hydrogen, aryl, Ar^9carbonyl, (Ar^8carbonyl) C_{1-6}alkyl, or wherein A is a bivalent radical of formula (d); wherein aryl, Ar^1, Ar^5, Ar^6, Ar^9 and Ar^8 are as defined in the corresponding definitions of claim 1.

7. A compound according to claim 6 wherein R^2 and R^3 are both hydrogen radicals.

8. A compound according to claim 7 wherein in the bivalent radical A having the formula (b) m is the integer 2 or 3 and n is 2, in the radical A having the formula (c) m is the integer 1 or 2 and n is the integer 2, and in the radical A of formula (d), m is the integer 1 or 2 and n is the integer 2.

9. A compound according to claim 8, wherein R^1 is halo, C_{1-6}alkyloxy, C_{1-6}alkylthio and cyano.

10. A compound according to claim 9, wherein R^1 is halo.

11. A compound of formula



(I"),

a pharmaceutically acceptable acid-addition salt and/or a possible stereochemically isomeric form and/or a possible tautomeric form thereof, wherein R^1, R^2, and R^3 are as defined in claim 1,

A^2 is a bivalent radical of formula (a), (c) or (d) as defined in claim 1, or A^2 is a bivalent radical of formula :

$$-C_mH_{2m}-\overset{\overset{R^{4-c}}{|}}{N}-C_nH_{2n}- \qquad (b\text{-}1),$$

wherein one of the hydrogen atoms within the radical C_mH_{2m} $C_{m-1}H_{2(m-1)}$ or C_nH_{2n} may be replaced by C_{1-6}alkyl or aryl; said aryl being phenyl optionally substituted with up to 3 substituents each independently selected from halo;

m and n are, each independently, integers of from 1 to 4 inclusive, the sum of m and n being 3, 4 or 5;

R^{4-c} is selected from aryl; thiazolyl; pyrimidinyl; quinolinyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; Ar^1 -C_{1-6}alkyl; diphenyl C_{1-6}alkyl; phenyl being substituted with Ar^2-carbonyl; pyridinyl, being optionally substituted with cyano or C_{1-6}alkyl; cyclohexyl and cyclohexenyl both being optionally substituted with up to two substituents independently selected from the group consisting of cyano and Ar^3; wherein aryl in the definition of R^{4-c} is as the aryl in the definition of R^4 in claim 1 and Ar^1, Ar^2, and Ar^3 are as defined in claim 1; provided that

i) when A^2 is a radical of formula (c) and R^6 is hydrogen, then R^5 is other than hydrogen, hydroxy or C_{1-6}alkyl;

ii) when R^2 and R^3 are hydrogen radicals and A is a radical of formula (b-1), then R^{4-c} is other than 3,3-diphenylpropyl;

iii) when R^2 and R^3 are hydrogen radicals and A^2 is a radical of formula (a), then R^1 is other than halo;

iv) when R^1 is chloro, R^2 and R^3 are hydrogen radicals and A^2 is a radical of formula (b-1), then R^{4-c} is other than 2-methoxyphenyl;

v) when R^1 is chloro, and A^2 is a bivalent radical of formula (b-1) then R^{4-c} is other then (dimethoxyphenyl)-methyl, (dimethoxyphenyl)ethyl, α-methylphenethyl or (2-methylphenyl)methyl;

vi) when R^1 is methoxy, and A^2 is a bivalent radical of formula (b-1), then R^{4-c} is other than (dimethoxyphenyl)ethyl or (dimethoxyphenyl)methyl.

12. A compound according to claim 11, wherein A^2 is a bivalent radical of formula (b-1), wherein R^{4-c} is aryl, pyridinyl, pyrimidinyl, C_{1-6}alkyloxycarbonyl, Ar^1C_{1-6}alkyl, diphenyl C_{1-6}alkyl, quinolinyl; or wherein A^2 is a bivalent radical of formula (c), wherein R^5 is hydrogen, aryl, Ar^5amino, (Ar^6)-(C_{1-6}alkyl)amino, hydroxy, indolyl and R^6 is hydrogen, aryl, Ar^8carbonyl, (Ar^8carbonyl) C_{1-6}alkyl, or wherein A^2 is a bivalent radical of formula (d);wherein each aryl, Ar^1 , Ar^5, Ar^6, Ar^8 and Ar^9 are as in corresponding definitions of claim 11.

13. A compound according to claim 12 wherein R^2 and R^3 are both hydrogen radicals.

14. A compound according to claim 13 wherein in the bivalent radical A^2 having the formula (b-1) m is the integer 2 or 3 and n is 2, in the radical A^2 having the formula (c) m is the integer 1 or 2 and n is the integer 2, and in the radical A^2 of formula (d), m is the integer 1 or 2 and n is the integer 2.

15. A compound according to claim 14 wherein R^1 is halo, C_{1-6}alkyloxy, C_{1-6}alkylthio and cyano.

16. A compound according to claim 15, wherein R^1 is halo.

17. A compound according to claim 11 wherein the compound of formula (I) is 3-bromo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine and the pharmaceutically acceptable acid addition salts thereof.

18. A compound according to claim 11 wherein the compound of formula (I) is 3-chloro-6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]pyridazine and the pharmaceutically acceptable acid addition salts thereof.

19. A pharmaceutical composition comprising a suitable pharmaceutical carri r and as an active ingredient a therapeutically effective amount of a compound as defined in any one of claims 4 to 18.

20. An anti-viral pharmaceutical composition, comprising a suitable pharmaceutical carrier and as an active ingredient an anti-virally effective amount of a compound as defined in any one of claims 4 to 18.

21. A method of preparing a pharmaceutical composition, characterized in that a therapeutically effective amount of a compound as defined in any of claims 4 to 18 is intimately mixed with suitable pharmaceutical carriers.

22. A process for preparing a compound as defined in claim 11, characterized by
a) alkylating an amine of formula

(II)

with a pyridazine of formula



(III),

wherein W represents a reactive leaving group, if desired, in a reaction-inert solvent, optionally in the presence of a base;
b) alkylating a pyridazinamine of formula



(I-a)

with a reagent of formula W-R^{4-a} wherein R^{4-a} is as R^4, as defined in claim 1 provided that it is not hydrogen, and W represents a reactive leaving group, if desired, in a reaction-inert solvent, optionally in the presence of a base, thus preparing a compound of formula



(I-b);

c) reductively N-alkylating a pyridazinamine of formula (I-a) with a carbonyl compound of formula

$$(R^{4-b-1})=C=O$$

said $(R^{4-b-1})=C=O$ being a compound of formula R^{4-b}-H, wherein a -CH_2 radical is oxidated to a carbonyl radical, and wherein R^{4-b} is Ar^7C_{1-6}alkyl, diphenyl C_{1-6}alkyl, cyclohexyl or cyclohexenyl, wherein Ar^7 is as defined in claim 1, in a reaction-inert solvent, thus preparing a compound of formula



(I-b);

and, if desired, converting the compounds of formula (I") into a therapeutically active non-toxic acid-addition salt form by treatment with an appropriate acid, or, conversely, converting the acid-addition

salt into the free base form with alkali; and/or preparing stereochemically isomeric forms thereof.

Revendications

1. Application, pour la préparation d'un médicament visant à traiter les maladies virales, d'un composé de formule



(I),

d'un de ses sels d'addition d'acides et/ou forme stéréochimiquement isomérique possible et/ou forme tautomérique possible pharmaceutiquement acceptable dans laquelle

R^1 est un membre choisi dans le groupe constitué par hydrogène, halo, 1 H -imidazol-1-yle, alcoyloxy en C_{1-6}, aryloxy, alcoylthio en C_{1-6}, arylthio, hydroxy, mercapto, amino, alcoyle en C_{1-6}-sulfinyle, alcoyle en C_{1-6}-sulfonyle, cyano, alcoyloxy en C_{1-6}-carbonyle, alcoyle en C_{1-6}-carbonyle, et alcoyle en C_{1-6} ;
où aryle dans la définition de R^1 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo, nitro et alcoyle en C_{1-6} ;

R^2 et R^3 représentent, chacun indépendamment, des membres choisis dans le groupe constitué par hydrogène et alcoyle en C_{1-6} , ou R^2 et R^3 combinés peuvent former un radical bivalent de formule -CH=CH-CH=CH- ;

A est un radical bivalent de formule :



(a),



(b),



(c), ou



(d);

où l'un des atomes d'hydrogène dans le radical C_mH_{2m}, $C_{m-1}H_{2(m-1)}$ ou C_nH_{2n}peut être remplacé par un alcoyle en C_{1-6} ou un aryle ; ledit aryle étant un phényle éventuellement substitué par jusqu'à trois substituants choisis indépendamment parmi halo;

m et n représentent, chacun indépendamment, des nombres entiers allant de 1 à 4 compris, la somme de m et n étant de 3, 4 ou 5 ; R^4 est un membre choisi dans le groupe constitué par hydrogène ; alcoyle en C_{1-6} ; aryle ; thiazolyle ; pyrimidinyle ; quinolinyle ; alcoyle en C_{1-6}-carbonyle ; alcoyloxy en C_{1-6}-carbonyle ; Ar^1 -alcoyle en C_{1-6} ; diphényl-alcoyle en C_{1-6} ; phényle substitué par un Ar^2-carbonyle ; pyridinyle, éventuellement substitué par un cyano ou un alcoyle en C_{1-6} ; cyclohexyle et cyclohexényle, tous deux éventuellement substitués par jusqu'à deux substituants choisis indépendamment dans le groupe constitué par cyano t Ar^3 ;
où aryle dans la définition de R^4 est un phényle, éventuellement substitué par jusqu'à trois substituants, chacun choisi indépendamment parmi halo, alcoyle en C_{1-6}, trifluorométhyle, nitro, alcoyloxy en C_{1-6}, amino, hydroxy, alcoyloxy en C_{1-5}-carbonyle et naphtalényle ;

Ar^1 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépen-

damment parmi alcoyle en C_{1-6} ;

Ar^2 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo ;

Ar^3 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo ;

R^5 est un hydrogène ; alcoyle en C_{1-6} ; aryle ; hydroxy ; alcoyloxy en C_{1-6} ; Ar^4oxy ; alcoyloxy en C_{1-6} substitué par une morpholine, pyrrolidine ou pipéridine ; amino ; (alcoyloxy en C_{1-6}-carbonyle)-amino ; Ar^5 -amino ; (Ar^5)(alcoyle en C_{1-6})amino ; (phényl-alcoyle en C_{1-6})amino ; (phényl-alcényle en C_{2-6})amino ; (phényl-alcényle en C_{2-6})(alcoyle en C_{1-6}) amino ; phénylcarbonyloxy ;

Ar^4 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo et alcoyle en C_{1-6} ;

Ar^5 est un phényle éventuellement substitué par jusqu,à trois substituants choisis chacun indépendamment parmi halo, alcoyle en C_{1-6}, trifluorométhyle ;

Ar^6 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi alcoyle en C_{1-6} ;

R^6 est un hydrogène ; aryle ; alcoyle en C_{1-6} ; (alcoyle en C_{1-6}-carbonylamino)alcoyle en C_{1-6} , Ar^7-alcoyle en C_{1-6} ; Ar^8-carbonyle-alcoyle en C_{1-6} ; aminocarbonyle ; Ar^9carbonyle ; phénylaminocarbonyle ; (phényl-alcoyle en C_{1-6}) carbonyle : alcoyloxy en C_{1-6}-carbonyle ; indolyle ; pyridinyle ;

Ar^7 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo et alcoyle en C_{1-6} ;

Ar^8 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo ;

Ar^9 est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo et trifluorométhyle ;

R^7 et R^8 représentent, chacun indépendamment, des membres choisis dans le groupe constitué par hydrogène, alcoyle en C_{1-6} , aryle, Ar^{10} -alcoyle en C_{1-6} et pyridinyle ;

où Ar^{10} est un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo ;

où aryle tel que dans les définitions de R^5, R^6, R^7 et R^8 est un phényle, éventuellement substitué par jusqu'à trois substituants, chacun choisi indépendamment dans le groupe constitué par halo, alcoyle en C_{1-6}, trifluorométhyle, nitro, amino, alcoyloxy en C_{1-6}, hydroxy et alcoyloxy en C_{1-6}-carbonyle ; thiényle ; et naphtalényle.

2. Application d'une composition comprenant un composé de formule (I), d'un de ses sels d'addition d'acides pharmaceutiquement acceptable, ou d'un de ses stéréoisomères, tels que définis dans la revendication 1, et un support pharmaceutique approprié, pour la préparation d'un médicament antiviral.

3. Application selon la revendication 1 ou 2 à la préparation d'un médicament anti-rhinoviral.

4. Composé de formule (I) selon la revendication 1, où R^4 est différent d'un 3,3-diphényl-propyle lorsque R^1, R^2 et R^3 représentent des radicaux hydrogène et A est un radical de formule (b) ;



est différent d'un pipéridinyle, lorsque R^1 est un hydrogène et R^2 et R^3 réunis forment un radical CH = CH-CH = CH bivalent ;



est différent d'un pipéridinyle et d'un hexahydro-1 H -azépinyle, lorsque R^1 est un halo, R^2 est un alcoyle en C_{1-6} et R^3 est un hydrogène ;

R^4 st différent d'un (diméthoxyphényl)-méthyle, (diméthoxyphényl)éthyle, α-méthyl-phénéthyle ou (2-méthylphényl)méthyle, lorsque R^1 est un chloro ou un méthoxy et A est un radical de formule (b), pour application comme médicament.

5. Composé de formule (I) selon la revendication 4 pour application comme médicament antiviral.

6. Composé selon la revendication 4 ou 5, où A est un radical bivalent de formule (b) où R^4 est un aryle, pyridinyle, pyrimidinyle, alcoyloxy en C_{1-6}-carbonyl , Ar^1-alcoyle en C_{1-6} , diphényl-alcoyle n C_{1-6}, quinolinyle ou bien où A est un radical bivalent de formule (c) où R^5 est un hydrogène, aryle, Ar^5 amino, (Ar^6)(alcoyle en C_{1-6})amino, hydroxy, indolyle et R^6 est un hydrogène, aryle, Ar^9 carbonyle, (Ar^8carbonyl)alcoyle en C_{1-6}, ou bien où A est un radical bivalent de formule (d) ; où aryle, Ar^1, Ar^5, Ar^6, Ar^9 et Ar^8 sont tels que définis dans les définitions correspondantes de la revendication 1.

7. Composé selon la revendication 6, dans lequel R^2 et R^3 représentent tous deux des radicaux hydrogène.

8. Composé selon la revendication 7 dans lequel dans le radical bivalent A de formule (b) m est le nombre entier 2 ou 3 et n vaut 2, dans le radical A de formule (c) m est le nombre entier 1 ou 2 et n est le nombre entier 2, et dans le radical A de formule (d), m est le nombre entier 1 ou 2 et n est le nombre entier 2.

9. Composé selon la revendication 8, dans lequel R' est un halo, alcoyloxy en C_{1-6}, alcoylthio en C_{1-6} et cyano.

10. Composé selon la revendication 9, dans lequel R' est un halo.

11. Composé de formule



(I"),

un de ses sels d'addition d'acides et/ou forme stéréochimiquement possible et/ou forme tautomérique possible pharmaceutiquement acceptable, dans lequel R^1, R^2 et R^3 sont tels que définis dans la revendication 1,

A^2 est un radical bivalent de formule (a), (c) ou (d) tel que défini dans la revendication 1, ou A^2 est un radical bivalent de formule



(b-1),

où l'un des atomes d'hydrogène dans le radical C_mH_{2m}, $C_{m-1}H_{2(m-1)}$ ou C_nH_{2n} peut être remplacé par un alcoyle en C_{1-6} ou un aryle, ledit aryle étant un phényle éventuellement substitué par jusqu'à trois substituants choisis chacun indépendamment parmi halo ;

m et n représentent, chacun indépendamment, les nombres entiers allant de 1 à 4 compris, la somme de m et n étant de 3, 4 ou 5 ;

R^{4-c} est choisi parmi aryle ; thioazolyle ; pyrimidinyle ; quinolinyle ; alcoyle en C_{1-6}-carbonyle ; alcoyloxy en C_{1-6}-carbonyle ; Ar^1-alcoyle en C_{1-6} ; diphényl-alcoyle en C_{1-6} ; phényle substitué par un Ar^2-carbonyle ; pyridinyle, éventuellement substitué par un cyano ou un alcoyle en C_{1-6} ; cyclohexyle et cyclohexényle, tous deux éventuellement substitués par jusqu'à deux substituants choisis indépendamment dans le groupe constitué par cyano et Ar^3 ; où aryle dans la définition de R^{4-c} est comme l'aryle dans la définition de R^4 dans la revendication 1, et Ar^1, Ar^2 et Ar^3 sont tels que définis dans la revendication 1 ;

sous réserve que

i) lorsque A^2 est un radical de formule (c) et R^6 est un hydrogène, alors R^5 est différent d'un hydrogène, hydroxy ou alcoyle en C_{1-6} ;

ii) lorsque R^2 et R^3 représ ntent des radicaux hydrogène et A est un radical de formule (b-1), alors

R^{4-c} est différent d'un 3,3-diphénylpropyle ;
iii) lorsque R^2 et R^3 représentent des radicaux hydrogène et A^2 est un radical de formule (a), alors R^1 est différent d'un halo ;
iv) lorsque R^1 est un chloro, R^2 et R^3 représentent des radicaux hydrogène et A^2 est un radical de formule (b-1), alors R^{4-c} est différent d'un 2-méthoxyphényle ;
v) lorsque R^1 est un chloro, et A^2 est un radical bivalent de formule (b-1), alors R^{4-c} est différent d'un (diméthoxyphényl)-méthyle, (diméthoxyphényl)éthyle, α-méthylphénéthyle ou (2-méthylphényl)-méthyle ;
vi) lorsque R^1 est un méthoxy, et A^2 est un radical bivalent de formule (b-1), alors R^{4-c} est différent d'un (diméthoxyphényl)-éthyle ou d'un (diméthoxyphényl)méthyle.

12. Composé selon la revendication 11, dans lequel A^2 est un radical bivalent de formule (b-1), où R^{4-c} est un aryle, pyridinyle, pyrimidinyle, alcoyloxy en C_{1-6}-carbonyle, Ar^1 -alcoyle en C_{1-6}, diphényl-alcoyle en C_{1-6}, quinolinyle, ou bien où A^2 est un radical bivalent de formule (c), où R^5 est un hydrogène, aryle, Ar^5-amino, (Ar^6)-(alcoyle en C_{1-6})amino, hydroxy, indolyle et R^6 est un hydrogène, aryle, Ar^9-carbonyle, (Ar^8-carbonyle)-alcoyle en C_{1-6}, ou bien où A^2 est un radical bivalent alcoyle en C_{1-6}, ou bien où A^2 est un radical bivalent de formule (d) ; où chaque radical aryle, Ar^1, Ar^5, Ar^6, Ar^8 et Ar^9 est tel que dans les définitions correspondantes de la revendication 11.

13. Composé selon la revendication 12, dans lequel R^2 et R^3 sont tous deux des radicaux hydrogène.

14. Composé selon la revendication 13, dans lequel dans le radical bivalent A^2 de formule (b-1), m est le nombre entier 2 ou 3 et n vaut 2, dans le radical A^2 de formule (c), m est le nombre entier 1 ou 2 et n est le nombre entier 2 et dans le radical A^2 de formule (d) m est le nombre entier 1 ou 2 et n est le nombre entier 2.

15. Composé selon la revendication 14, dans lequel R^1 est un halo, alcoyloxy en C_{1-6}, alcoylthio en C_{1-6} et cyano.

16. Composé selon la revendication 15, dans lequel R^1 est un halo.

17. Composé selon la revendication 11 dans lequel le composé de formule (I) est la 3-bromo-6-[4-(3-méthylphényl)-1-pipérazinyl] pyridazine et ses sels d'addition d'acides pharmaceutiquement acceptables.

18. Composé selon la revendication 11, dans lequel le composé de formule (I) est la 3-chloro-6-[3,6-dihydro-4-(3-méthylphényl)-1(2 H)-pyridinyl]pyridazine et ses sels d'addition d'acides pharmaceutiquement acceptables.

19. Composition pharmaceutique comprenant un support pharmaceutique approprié et comme ingrédient actif une quantité thérapeutiquement efficace d'un composé tel que défini dans l'une quelconque des revendications 4 à 18.

20. Composition pharmaceutique antivirale comprenant un support pharmaceutique approprié et comme ingrédient actif une quantité antivirale efficace d'un composé tel que défini dans l'une quelconque des revendications 4 à 18.

21. Procédé de préparation d'une composition pharmaceutique, caractérisé en ce qu'on mélange intimement une quantité thérapeutiquement efficace d'un composé tel que défini dans l'une quelconque des revendications 4 à 18 avec des supports pharmaceutiques appropriés.

22. Procédé de préparation d'un composé tel que défini dans la revendication 11, caractérisé en ce que
a) on alcoyle une amine de formule

(II)

avec une pyridazine de formule



(III),

où W représente un groupe partant réactif, si on le désire, dans un solvant inerte vis-à-vis de la réaction, éventuellement en présence d'une base;
b) on alcoyle une pyridazine de formule



(I-a)

avec un réactif de formule

(IV)

où R^{4-a} est tel que R^4 défini dans la revendication 1, sous réserve qu'il ne soit pas un hydrogène et W représente un groupe partant réactif, si on le désire, dans un solvant inerte vis-à-vis de la réaction, éventuellement en présence d'une base, préparant ainsi un composé de formule



(I-b);

c) on N-alcoyle de façon réductrice une pyridazinamine de formule (I-a) avec un composé carbonyle de formule

$(R^{4-b-1}) = C = O$

ledit $(R^{4-b-1}) = C = O$ étant un composé de formule R^{4-b}-H, où un radical $-CH_2$ est oxydé en un radical carbonyle, et où R^{4-b} est un Ar^1-alcoyle en C_{1-6}, diphényl-alcoyle en C_{1-6}, cyclohexyle ou cyclohéxényle, où Ar^1 est tel que défini dans la revendication 1, dans un solvant inerte vis-à-vis de la réaction, préparant ainsi un composé de formule



(I-b);

et, si on le désire, on transforme les composés de formule (I") en une forme sel d'addition d'acides non toxique thérapeutiquement active par traitement avec un acide approprié ou, inversement, on transforme le sel d'addition d'acides en la forme base libre avec une base, et/ou on prépare ses formes stéréochimiquement isomériques.

Ansprüche

1. Verwendung iner Verbindung der Formel



(I),

eines pharmazeutisch annehmbaren Säureadditionssalzes und/oder einer möglichen stereochemisch isomeren Form und/oder einer möglichen tautomeren Form hievon zur Herstellung eines Arzneimittels zur Behandlung von Viruserkrankungen, worin

R^1 ein Rest ist, ausgewählt aus der Gruppe bestehend aus Wasserstoff, Halogen, 1 H -Imidazol-1-yl, C_{1-6}Alkyloxy, Aryloxy, C_{1-6}Alkylthio, Arylthio, Hydroxy, Mercapto, Amino, C_{1-6}Alkylsulfinyl, C_{1-6}Alkylsulfonyl, Cyano C_{1-6}-Alkyloxycarbonyl, C_{1-6}Alkylcarbonyl und C_{1-6}Alkyl;worin Aryl in der Definition von R^1 Phenyl bedeutet, das wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils voneinander unabhängig aus Halogen, Nitro und C_{1-6}Alkyl ausgewählt sind;

R^2 und R^3 Reste sind, welche jeweils unabhängig voneinander aus der Gruppe, bestehend aus Wasserstoff und C_{1-6}Alkyl ausgewählt sind, oder R^2 und R^3 zusammengenommen einen zweiwertigen Rest der Formel -CH = CH-CH = CH- ausbilden können;

A ein zweiwertiger Rest der Formel:



(a),

(b),



(c) oder

(d)

ist, worin eines der Wasserstoffatome im Rest C_mH_{2m},$C_{m-1}H_{2(m-1)}$ oder C_nH_{2n} durch C_{1-6}Alkyl oder Aryl ersetzt sein kann, welches Aryl Phenyl bedeutet, das wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen ausgewählt sind;

m und n jeweils unabhängig voneinander ganze Zahlen von 1 bis einschließlich 4 bedeuten, wobei die Summe von m und n 3, 4 oder 5 beträgt;

R^4 ein Rest ist, ausgewählt von der Gruppe bestehend ans Wasserstoff, C_{1-6}Alkyl; Aryl, Thiazolyl, Pyrimidinyl, Chinolinyl; C_{1-6}Alkylcarbonyl; C_{1-6}Alkyloxycarbonyl: Ar^1C_{1-6}Alkyl; Diphenyl C_{1-6}alkyl; Phenyl, das mit Ar^2Carbonyl substituiert ist;Pyridinyl, das wahlweise mit Cyano oder C_{1-6}Alkyl substituiert ist; Cyclohexyl und Cyclohexenyl, welche beide wahlweise mit bis zu 2 Substituenten substituiert sind, welche unabhängig ans der Gruppe bestehend ans Cyano und Ar^3 ausgewählt sind;
worin Aryl in der Definition von R^4 Phenyl bedeutet, das wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen, C_{1-6}Alkyl, Trifluormethyl, Nitro, C_{1-6}Alkyloxy, Amino, Hydroxy und C_{1-6}Alkyloxycarbonyl ausgewählt sind; und Naphtalenyl ist;

Ar^1 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus C_{1-6}Alkyl ausgewählt sind;

Ar^2 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils voneinander unabhängig aus Halog n ausgewählt sind;

Ar^3 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen ausgewählt sind;

R^5 Wasserstoff; C_{1-6}Alkyl; Aryl; Hydroxy; C_{1-6}Alkyloxy; Ar^4Oxy; C_{1-6}Alkyloxy, w lches mit Morpholin, Pyrrolidin oder Piperidin substituiert ist; Amino; (C_{1-6}Alkyoxycarbonyl)amino; Ar^5Amino; (Ar^6)(C_{1-6}Alkyl)amino; (Phenyl C_{1-6}alkyl)amino; (Phenyl C_{2-6}alkenyl)amino; (Phenyl C_{2-6}alkenyl) (C_{1-6}Alkyl)-

amino, Phenylcarbonyloxy darstellt;
Ar^4 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen und C_{1-6}Alkyl ausgewählt sind;
Ar^5 Phenyl bedeutet, welch s wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen, C_{1-6}Alkyl, Trifluormethyl ausgewählt sind;
Ar^6 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten sub stituiert ist, welche jeweils unabhängig voneinander aus C_{1-6}Alkyl ausgewählt sind;
R^6 Wasserstoff;Aryl; C_{1-6}Alkyl; (C_{1-6}Alkylcarbonylamino) C_{1-6}alkyl, Ar^7C_{1-6}Alkyl; Ar^8 Carbonyl C_{1-6}alkyl; Aminocarbonyl; Ar^9Carbonyl; Phenylaminocarbonyl; (Phenyl C_{1-6}alkyl)carbonyl, C_{1-6} Alkyloxycarbonyl; Indolyl; Pyridinyl darstellt;
Ar^7 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen und C_{1-6}Alkyl ausgewählt sind;
Ar^8 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen ausgewählt sind;
Ar^9 Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen und Trifluormethyl ausgewählt sind;
R^7 und R^8 Reste sind, welche jeweils unabhängig voneinander aus der Gruppe, bestehend aus Wasserstoff, C_{1-6}Alkyl, Aryl, $Ar^{10}C_{1-6}$Alkyl und Pyridinyl ausgewählt sind;
worin Ar^{10} Phenyl bedeutet, welches wahlweise mit bis zu 3 Substituenten substiuiert ist, welche jeweils unabhängig voneinander aus Halogen ausgewählt sind;
worin Aryl wie in den Definitionen von R^5, R^6 R^7 und R^8 Phenyl ist, welches wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus der Gruppe, bestehend aus Halogen, C_{1-6}Alkyl, Trifluormethyl, Nitro, Amino , C_{1-6}Alkyloxy, Hydroxy und C_{1-6}Alkyloxycarbonyl; Thienyl; und Naphthalenyl ausgewählt sind.

2. Verwendung einer Zusammensetzung, welche eine Verbindung der Formel (I), ein pharmazeutisch annehmbares Säureadditionssalz hievon oder ein Stereoisomer hievon, wie in Anspruch 1 definiert, und einen geeigneten pharmazeutischen Träger enthält, zur Herstellung eines anti-Virus-Arzneimittels.

3. Verwendung nach Anspruch 1 oder 2 zur Herstellung eines anti-rhinoviralen Arzneimittels.

4. Verbindung der Formel (I), wie in Anspruch 1 definiert, worin R^4 eine andere Bedeutung als 3,3-Diphenylpropyl besitzt, wenn R^1, R^2 und R^3 Wasserstoffreste sind und A einen Rest der Formel (b) darstellt;



kein Piperidinyl ist, wenn R^1 Wasserstoff darstellt und R^2 und R^3einen zweiwertigen CH=CH-CH=CH-Rest ausbilden;



kein Piperidinyl und kein Hexahydro-1 H -azepinyl ist, wenn R^1 für Halogen steht, R^2 C_{1-6}Alkyl bedeutet und R^3 Wasserstoff darstellt; R^4 eine andere Bedeutung als (Dimethoxyphenyl)methyl, (Dimethoxyphenyl)ethyl, alpha-Methyl-phenethyl oder (2-Methylphenyl)methyl besitzt, wenn R^1 Chlor oder Methoxy bedeutet und A einen Rest der Formel (b) darstellt, zur Verwendung als Arzneimittel.

5. Verbindung der Formel (I), wie in Anspruch 4 definiert, zur Verwendung als anti-Virus-Arzneimittel.

6. Verbindung nach Anspruch 4 oder 5, worin A ein zweiwertiger Rest der Formel (b) ist, worin R^4 für Aryl, Pyridinyl, Pyrimidinyl, C_{1-6}Alkyloxycarbonyl, Ar^1C_{1-6}Alkyl, Diphenyl C_{1-6}alkyl, Chinoliny, steht oder worin A ein zweiwertiger Rest der Form I (c) ist, worin R^5 Wasserstoff, Aryl, Ar^5Amino (Ar^6)(C_{1-6}Alkyl)amino, Hydroxy, Indolyl und R^6 Wasserstoff, Aryl, Ar^9Carbonyl, (Ar^8Carbonyl) C_{1-6}alkyl bedeut t; oder worin A ein zweiwertiger Rest der Formel (d) ist; worin aryl, Ar^1, Ar^5, Ar^6, Ar^9 und Ar^8 wie in den ntsprechenden Definitionen von Anspruch 1 definiert sind.

7. Verbindung nach Anspruch 6, worin R^2 und R^3 beide Wasserstoffreste sind.

8. Verbindung nach Anspruch 7, worin im zweiwertigen Rest A mit der Formel (b) m die ganze Zahl 2 oder 3 ist und n den Wert 2 besitzt, im Rest A mit der Formel (c) m die ganze Zahl 1 oder 2 ist und n die ganze Zahl 2 ist, und im Rest A mit der Formel (d) m die ganze Zahl 1 oder 2 ist und n die ganze Zahl 2 ist.

9. Verbindung nach Anspruch 8, worin R^1 für Halogen, C_{1-6}Alkyloxy, C_{1-6}Alkylthio und Cyano steht.

10. Verbindung nach Anspruch 9, worin R^1 Halogen bedeutet.

11. Verbindung der Formel



(I"),

ein pharmazeutisch annehmbares Säureadditionssalz und/oder eine mögliche stereochemisch isomere Form und/oder eine mögliche tautomere Form hievon, worin R^1, R^2 und R^3 wie in Anspruch 1 definiert sind,
A^2 ein zweiwertiger Rest der Formel (a), (c) oder (d) ist, wie in Anspruch 1 definiert, oder A^2 ein zweiwertiger Rest der Formel:



(b-1) ist,

worin eines der Wasserstoffatome im Rest C_mH_{2m}, $C_{m-1}H_{2(m-1)}$ oder C_nH_{2n} durch C_{1-6}Alkyl oder Aryl ersetzt sein kann, welches Aryl Phenyl ist, das wahlweise mit bis zu 3 Substituenten substituiert ist, welche jeweils unabhängig voneinander aus Halogen ausgewählt sind;
m und n jeweils unabhängig voneinander ganze Zahlen von 1 bis einschließlich 4 sind, wobei die Summe von m und n 3, 4 oder 5 beträgt;
R^{4-c} ausgewählt ist aus Aryl; Thiazolyl; Pyrimidinyl;Chinolinyl; C_{1-6}Alkylcarbonyl; C_{1-6}Alkyloxycarbonyl; Ar^1 C_{1-6} Alkyl; Diphenyl C_{1-6}alkyl; Phenyl, welches mit Ar^2 Carbonyl substituiert ist; Pyridinyl, welches wahlweise mit Cyano oder C_{1-6}Alkyl substituiert ist; Cyclohexyl und Cylohexenyl, welche beide wahlweise mit bis zu zwei Substituenten substituiert sind, welche unabhängig von der Gruppe bestehend aus Cyano und Ar^3 ausgewählt sind; worin Aryl in der Definition von R^{4-c} wie das Aryl in der Definition von R^4 in Anspruch 1 definiert ist und Ar^1, Ar^2 und Ar^3 wie in Anspruch 1 definiert sind;
mit der Maßgabe, daß
i) wenn A^2 ein Rest der Formel (c) ist und R^5 für Wasserstoff steht, R^5 eine andere Bedeutung als Wasserstoff, Hydroxy oder C_{1-6}Alkyl besitzt;
ii) wenn R^2 und R^3 Wasserstoffreste darstellen und A ein Rest der Formel (b-1) ist, R^{4-c} nicht 3,3-Diphenylpropyl bedeutet;
iii) wenn R^2 und R^3 Wasserstoffreste sind und A^2 ein Rest der Formel (a) ist, R^1 eine andere Bedeutung als Halogen besitzt;
iv) wenn R^1 Chlor ist, R^2 und R^3 Wasserstoffreste darstellen und A^2 einen Rest der Formel (b-1) bedeutet, R^{4-c} nicht 2-Methoxyphenyl ist;
v) wenn R^1 Chlor ist und A^2 einen zweiwertigen Rest der Formel (b-1) darstellt, R^{4-c} nicht (Dimethoxyphenyl)methyl, (Dimethoxyphenyl)ethyl, alpha-Methylphenethyl oder (2-Methylphenyl)-m thyl ist;
vi) wenn R^1 Methoxy bedeutet und A^2 einen zweiw rtigen Rest der Formel (b-1) darstellt, R^{4-c} nicht (Dimethoxyphenyl)ethyl oder (Dimethoxyphenyl)methyl ist.

12. Verbindung nach Anspruch 11, worin A^2 ein zweiwertiger Rest der Form l (b-1) ist, worin R^{4-c} für Aryl, Pyridinyl, Pyrimidinyl, C_{1-6}Alkyloxycarbonyl, Ar^1C_{1-6}Alkyl, Diphenyl C_{1-6}alkyl, Chinolinyl steht; oder

worin A^2 ein zweiwertiger Rest der Formel (c) ist, worin R^5 für Wasserstoff, Aryl, Ar^5amino,(Ar^6)(C_{1-6}Alkyl)amino, Hydroxy, Indolyl steht und R^6 Wasserstoff, Aryl, Ar^9carbonyl, (Ar^8Carbonyl) C_{1-6}alkyl bedeutet, oder worin A^2 ein zweiwertiger Rest der Formel (d) ist; worin jedes Aryl Ar^1, Ar^5, Ar^6, Ar^8 und Ar^9 wi in den entsprechenden Definitionen in Anspruch 11 sind.

13. Verbindung nach Anspruch 12,worin R^2 und R^3 beide Wasserstoffreste sind.

14. Verbindung nach Anspruch 13, worin im zweiwertigen Rest A^2 mit der Formel (b-1) m die ganze Zahl 2 oder 3 ist und n 2 beträgt, im Rest A^2 mit der Formel (c) m die ganze Zahl 1 oder 2 ist und n die ganze Zahl 2 ist und im Rest A^2 der Formel (d) m die ganze Zahl 1 oder 2 ist und n die ganze Zahl 2 ist.

15. Verbindung nach Anspruch 14, worin R^1 Halogen, C_{1-6}Alkyloxy, C_{1-6}Alkylthio und Cyano bedeutet.

16. Verbindung nach Anspruch 15, worin R^1 Halogen darstellt.

17. Verbindung nach Anspruch 11, worin die Verbindung der Formel (I) 3-Brom-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazin und eines der pharmazeutisch annehmbaren Säureadditionssalze hievon ist.

18. Verbindung nach Anspruch 11, worin die Verbindung der Formel (I) 3-Chlor-6-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]pyridazin und eines der pharmazeutisch annehmbaren Säureadditionssalze hievon ist.

19. Pharmazeutsiche Zusammensetzung, umfassend einen geeigneten pharmazeutischen Träger und als wirksamen Bestandteil eine therapeutisch wirksame Menge einer Verbindung, wie in einem der Ansprüche 4 bis 18 definiert.

20. Pharmazeutische anti-Virus-Zusammensetzung, umfassend einen geeigneten pharmazeutischen Träger und als wirksamen Bestandteil eine wirksame anti-Virus-Menge einer Verbindung, wie in einem der Ansprüche 4 bis 18 definiert.

21. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, dadurch gekennzeichnet, daß eine therapeutisch wirksame Menge einer Verbindung, wie in einem der Ansprüche 4 bis 18 definiert, mit geeigneten pharmazeutischen Trägern innig vermischt wird.

22. Verfahren zur Herstellung einer wie in Anspruch 11 definierten Verbindung, gekennzeichnet durch
a) Alkylieren eines Amins der Formel



(II)

mit einem Pyridazin der Formel



(III),

worin W eine reaktive Leaving-Gruppe darstellt, wenn gewünscht in einem reaktionsinerten Lösungsmittel, wahlweis in Gegenwart einer Base;
b) Alkylieren eines Pyridazinamins der Formel



(I-a)

mit einem Reagens der Formel

(IV),

worin R^{4-a} die gleiche Bedeutung wie R^4, welches in Anspruch 1 definiert ist, besitzt, mit der Maßgabe, daß es nicht Wasserstoff bedeutet ,und W eine reaktive Leaving-Gruppe darstellt, wenn gewünscht, in einem reaktionsinerten Lösungsmittel, wahlweise in Gegenwart einer Base, wodurch eine Verbindung der Formel



(I-b)

hergestellt wird;

c) reduktives N-Alkylieren eines Pyridazinamins der Formel (I-a) mit einer Carbonylverbindung der Formel $(R^{4-b-1})=C=O$, welche $(R^{4-b-1})=C=O$ eine Verbindung der Formel R^{4-b}-H ist, worin ein $-CH_2$-Rest zu einem Carbonylrest oxidiert ist, und worin R^{4-b} Ar^1C_{1-6}Alkyl, Diphenyl C_{1-6}alkyl, Cyclohexyl oder Cylohexenyl bedeutet, worin Ar^1 wie in Anspruch 1 definiert ist, in einem reaktionsinerten Lösungsmittel, wodurch eine Verbindung der Formel



(I-b)

hergestellt wird; und , wenn gewünscht, Überführen der Verbindungen der Formel (I") in eine therapeutischen wirksame nicht-toxische Säureadditionssalzform durch Behandlung mit einer geeigneten Säure oder umgekehrt, Überführen des Säureadditionssalzes in die freie Basenform mit Alkali- und/oder Herstellen stereochemisch isomerer Formen hievon.